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ABSTRACT
The research herein aimed to increase our understanding about potential roles of
adrenergic receptor subtypes in epileptic seizures and seizure-like (epileptiform)
phenomena. Previous observations in our laboratory led us to hypothesize that the α1Aadrenergic receptor is a critical component of the modulatory role of the α1-adrenergic
receptor, and more broadly, norepinephrine, on epileptiform and seizure activity. We
utilized a combination of genetic and pharmacological manipulation to elucidate specific
effects of the α1A-adrenergic receptor subtype on altering hyperactivity in models of
epilepsy, both in slice and in vivo. This research sought to address three main research
questions: (1) What are the specific contributions of α1-adrenergic receptor subtypes to
alterations of epileptiform activity?; (2) Do any α1A-adrenergic receptor alterations to
epileptiform activity translate from tissue slices to in vivo models?; (3) Can we utilize
genetically modified mice to identify possible candidate cell types of α1A-adrenergic
receptor expression? All of these questions are an attempt to circumvent historical
difficulties with a lack of specificity of subtype-specific ligands and antibodies.
We found that α1A-adrenergic receptor activation confers an antiepileptic effect,
which was consistent with expectations formulated from previous observations of indirect
neural circuit modulation. Specifically, previous observations from our laboratory
strongly suggest that α1A-adrenergic receptors confer hyperexcitation of hippocampal
inhibitory interneurons. Interestingly, our approach also revealed that the α1A-adrenergic
receptor is important for maintaining optimal brain excitability, both in vitro and in vivo.
This is exemplified by our characterization of unprovoked, recurrent seizures and
exacerbated epileptiform burst frequency in α1A-adrenergic receptor knockout mice.
xvi

Meanwhile, in vitro studies suggested little role for the other centrally expressed α1adrenergic receptor, the α1B-adrenergic receptor, within our model systems. Our
investigation of α1A-adrenergic receptor expression used fluorescence microscopy and
genetically-induced receptor reporter expression to better understand the observed
phenomena. We show evidence for occasional α1A-adrenergic receptor reporter colocalization on parvalbumin-expressing puncta and, more broadly, reporter localization
consistent with inhibitory interneuron expression, within the mouse hippocampus.
Collectively, these findings suggest that the α1A-adrenergic receptor contributes to
demonstrated antiepileptic effects of the adrenergic system and that loss of this receptor
subtype is demonstrably unfavorable to the maintenance of normal brain excitability and
to the resistance of epileptiform activity. Additionally, our findings demonstrate the
value of genetically modified animal models when chemical characterization is
infeasible. These findings suggest that the α1A-adrenergic receptor may represent a
promising and unexplored therapeutic target and/or biomarker for epilepsy. Importantly,
the proposed therapeutic pathway for α1A-adrenergic receptor modulation is novel and
may be used more broadly to evaluate the potential of interneuron-modulation in
epilepsy. Even today, one-third of all people with epilepsy have no effective therapeutic
option.

xvii

CHAPTER I
INTRODUCTION
Science is a sluggish beast of burden from which constant failure bestows the
greatest knowledge. Science is a titillating gem whose sheen holds untold riches just out
of reach. Today, much of the profound discoveries in science are incremental in nature.
The significance of many findings are not well-understood for decades and sometimes
lifetimes. The research herein represents the collaborative efforts of many researchers,
past and present, working diligently to elucidate the puzzles of nature.
The interest of this dissertation was to investigate whether a receptor with roots in
the origins of our laboratory could prove a novel and useful approach to treating a disease
which has burdened humankind throughout much of our history and still represents a
significant burden to modern-day medicine. More directly, we aimed to better
understand the physiological mechanism for the actions of the noradrenergic system in
epilepsy. Research of these mechanisms has led us to the hypothesize that the α1Aadrenergic receptor (AR) is responsible for α1-AR-mediated antiepileptic properties. Our
research here explored this hypothesis by isolating α1-AR subtype contributions;
characterized potential translatability to an in vivo seizure model; and identified
representative α1A-AR expression patterns within the mouse hippocampus. Unexpectedly,
our research also led to findings pertaining to the potential consequences of α1A-AR lossof-function.
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Seizures, the functional consequence of epilepsy are thought to be the product of
network dysfunction. Likewise, the noradrenergic system is thought to act in the brain as
a large-scale modulator; thus, these concepts seemed to be a natural pairing.
Unsurprisingly, there exists significant evidence to suggest a role for the noradrenergic
system in epilepsy. However, for reasons we will discuss, the physiological participants
in these antiepileptic effects remain poorly understood.
The Noradrenergic System
Norepinephrine and Epinephrine
Norepinephrine and epinephrine are endogenous catecholamine signaling
molecules, which modulate diverse alterations in the periphery and in the brain. Both
norepinephrine and epinephrine are produced within the adrenal medulla, sympathetic
nervous system, and central nervous system (Molnoff et al., 1971). Epinephrine is
mostly synthesized in the medulla of the adrenal glands, where it is released into the
bloodstream as a hormone, especially in the presence of stressful stimuli. Norepinephrine
is also produced here and released to a lesser extent (Lymperopoulos, 2016; Currie,
2010). Norepinephrine is produced in large part by the sympathetic and central nervous
systems. (Mollnoff et al., 1971; Simpson et al., 2007). The production of norepinephrine
within the central nervous system is discussed later, in detail.
Norepinephrine and epinephrine are derivatives of the amino acid tyrosine. The
dominant pathway for norepinephrine and epinephrine synthesis is initiated by the
conversion of tyrosine to DOPA, via the rate-limiting enzyme tyrosine hydroxylase
(Nagatsu et al., 1964). DOPA is then converted to dopamine, which subsequently
undergoes β-hydroxylation to form norepinephrine, via dopamine β-hydroxylase
2

(Kaufman, 1965; Weinshilboum1971). Finally, phenethanolamine-N-methyltransferase
converts norepinephrine to epinephrine by methylation of the amine of norepinephrine
(Molnoff et al., 1971). The synthesis of norepinephrine and epinephrine, as well as
minor synthesis pathways are illustrated in Figure 1.

Figure 1. Biosynthesis of Catecholamines. DBH-dopamine-, β-hydroxylase; NMTnonspecific methyltransferase; AAD-aromatic acid decarboxylase; PNMT phenylethanolamine-N -methyItransferase; CFE-catecholamine-forming enzyme.
Republished with permission of Annual Reviews, from Biochemistry of Catecholamines,
P. Molinoff, and, and J. Axelrod, Volume 40, 1971; permission conveyed through
Copyright Clearance Center, Inc.
Adrenergic Receptors
The ARs are the receptive elements to norepinephrine and epinephrine. ARs are a
family of seven transmembrane-domain G-protein coupled receptors (GPCRs)
(Lefkowitz, 2007; Rasmussen et al., 2007; Rasmussen et al., 2011; Westfield et al.,
2011). There are nine known genetically-unique adrenergic receptor subtypes; these are
the α1A-, α1B-, α1D-, α2A-, α2B-, α2C-, β1-, β2-, and β3-ARs (Bylund et al., 1994; Hieble et
3

al., 1995) (Fig. 2). These receptors are more generally classified as the α1-, α2-, or βARs and are differentiated based upon genetic similarities and differential affinities and
responsiveness to various adrenergic agonists and antagonists (Bylund, 2006; Lefkowitz,
1979). An additional classification criteria is the most commonly associated
heterotrimeric G-protein signaling protein; the α1-ARs associate with Gq/11 proteins, the
α2-ARs with Gi proteins, and the β-ARs with Gs proteins (Finch et al., 2006). The
classifications of G-proteins are based upon the characteristic α-subunit of the protein
complex (Finch et al., 2006). Gq/11 signaling results in activation of phospholipase C with
subsequent production of inositol triphosphate and diacylglycerol second messengers
(Black, 2012). Gs and Gi signaling either activates or inhibits adenylyl cyclase function,
respectively. Adenylyl cyclase produces cyclic adenosine monophosphate (cAMP), a
second messenger important for many physiological processes (Halls, 2017).
Differences between the AR subtypes have been more difficult to delineate
because a high degree of overlap between the binding sites leads to promiscuity towards
many ligands (Finch et al., 2006); this is especially apparent in the α1-ARs where only
two residues differentiate primary ligand binding site to the α1A-AR and α1B-AR (Hwa et
al., 1995; 1996). Demonstrated differences in efficacies in tissue and cell models are
attributed to several factors. The most well-understood factors to contribute to observed
differences in efficacies are cell-specific expression and localization and/or differences in
G-protein subtype binding (Finch et al., 2006); Additionally, there are several lines of
evidence suggesting AR alternative signal transduction pathways not associated with Gprotein alpha subunits (Koch, 1994; Crespo, 1995), or signaling independent of G-protein
second messenger pathways altogether (Tang et al., 1999; Xu et al., 1999; Pupo et al.,
4

2003; Wang, 2002; Lefkowitz, 2005). GPCRs sometimes also exhibit biased agonism,
wherein a ligand binds prior to inactive second messenger coupling, allowing for other
signal transducer couplings; this has been shown in several ARs (Wissler, 2018; DeGraff,
1999; Copik, 2015). A final layer of complexity to AR signaling is that these receptors
exhibit a high degree of heterogeneous cellular localization; this is made particularly
evident by the example of the α1D-AR, which, for unknown reasons, are mostly localized
to intracellular membranes. (McCune, 2000; Garcia-Sainz, 1999; Gisbert, 2000; Piascik
et al., 2006). As a result of these and other potential factors, many AR subtypes exhibit
disparate and sometimes opposing effects from other subtypes of that class when
activated.

Figure 2. Current Classification of the Adrenergic Receptors. Representation of
currently accepted adrenergic receptor classification based on successfully cloned
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receptors. Hierarchical scheme divides each pharmacologically-unique class (α1-, α2-, or
β-AR), followed by subtype division by pharmacological and genetic differentiations.
Our research has found functional evidence to suggest that the α1-ARs seem to be
expressed on inhibitory interneurons in the hippocampus (Bergles, 1996; Hillman, 2009).
This seems to be unique to the α1-ARs. Previous research in the Doze lab has identified
clear evidence of excitatory (pyramidal) cell β-AR and α2-AR function, but not of α1ARs (Jurgens et al., 2005; Jurgens et al., 2005b; Hillman et al., 2005; Hillman et al.,
2007; Jurgens et al., 2007; Goldenstein et al., 2009). The focus of this dissertation
research, α1-ARs, are typically thought of as excitatory in nature, but due to the
hypothesized expression on inhibitory interneurons, our findings show a counterintuitive
inhibitory effect on brain excitability.
Central Noradrenergic Neuraxis
In mammals, the bulk of central NE is produced in the locus coeruleus, a dorsal pontine
nuclear complex within the periventricular gray of the isthmus (Simpson et al., 2007;
Giorgi et al., 2004). Noradrenergic fibers form both ascending and descending tracts,
with the ascending tract exhibiting a high degree of collateralization, while the main
fibers form a dorsal tegmental bundle that extends anterior and ventrally to join the
medial forebrain bundle (Simpson et al., 2007). The NE produced by these neurons is
mainly released via volume transmission from non-synaptic varicosities (Aston-Jones,
2016). Noradrenergic fiber tracing suggests that each far-reaching, highly branched axon
innervates the entire cerebral cortex (Giorgi et al., 2004). Despite this apparently
unspecific and global innervation pattern, some areas, such as the hippocampus, receive
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direct innervations from noradrenergic axon terminals (Foote et al., 1983; Blackstad,
1967).
Together, the anatomy of the noradrenergic fibers and the volume transmission of
norepinephrine suggests a primary role for norepinephrine as a modulatory
neurotransmitter. Many lines of evidence support this claim, including studies showing
that norepinephrine alters neural oscillation patterns, which affects state of vigilance and
the sleep-wake cycle (Aston-Jones, et al., 1981; 1991; 1994; Giorgi, 2004). Because of
this broad action, region-specific actions of NE are thought to be conveyed by inherent
differences in the expression of NE receptors, which are the ARs.
Historical Perspectives and Classification of the Noradrenergic System
Despite our relatively limited understanding of the complex nature of the
noradrenergic system, it may be surprising that noradrenergic research underlies several
important advances in our understanding of receptors and cellular signaling. Around the
turn of the 20th century, John Abel published his work describing the isolation of the first
hormone, epinephrine (Abel, 1899; Bylund, 2006). However, it is worth noting that
others disputed his claim, especially Jokichi Takamine, who was working to extract the
hormone around the same time as early work by Abel and was the first to publish his
discovery of the pure crystalized form, which he referred to as Adrenalin (Arthur, 2015;
Takamine, 1901; Parascandola, 2010). Interestingly, it was not realized until later that
neither scientist had isolated pure epinephrine, though Takamine was closer, as his crystal
isolation only contained norepinephrine impurities (Parascandola, 2010). Interestingly,
though the controversy has mostly faded, remnants of this tumult exists in the regional
differences in terminology and inconsistencies of receptor nomenclature. Specifically,
7

while much of the world refers to the endogenous catecholamines, noradrenaline and
adrenaline, researchers and medical practitioners in the United States refers to the same
chemicals as norepinephrine and epinephrine, in recognition of Abel. However,
interestingly, the receptive elements are called adrenergic receptors, perhaps, as a
concession to recognize both Abel and Takamine. Regardless of the true discoverer, the
work of these researchers, as well as that of Thomas Aldrich, firmly placed noradrenergic
research at the forefront of many discoveries to come.
Shortly thereafter, Sir Henry Dale utilized epinephrine in his work describing the
effects of ergot alkaloids on epinephrine in the sympathetic nervous system, on the nature
of receptive mechanisms (Bylund, 2006; Schild, 1997; Dale, 1906). Norepinephrine was
discovered shortly after this initial flurry of discoveries. In the late 1940s, the laboratory
of Raymond Ahlquist furthered our understanding of receptors when his laboratory
utilized several norepinephrine and epinephrine synthetic analogs to demonstrate the
presence of multiple classes of receptors by showing that variable responses could be
elicited from the same agonist depending on the tissue studied (Ahlquist, 1948; Ahlquist,
1973). This work was a great advancement in our understanding, which provided the
antecedents of Receptor Theory. More generally, these findings provided a much greater
understanding of the physiology underlying the responses of our cells to stimuli.
Our current classification of the 9 distinct AR subtypes is the result of studious
pharmacological characterization and cloning studies. The pharmacological
characterizations of the ARs occurred in the decades after the discoveries of Ahlquist and
used this same basic approach to define several AR subtypes. The cloning studies which
followed implemented techniques to isolate purified receptors using affinity
8

chromatography. The purified proteins were digested and underwent amino acid
sequencing. From these crude sequences, the researchers would create hybridization
probes of the reverse-engineered potential DNA sequences, which were subsequently
used to create cloned DNA fragments. Finally, this DNA library was expressed and
pharmacologically characterized to cross-reference the newly cloned protein to known
pharmacological isolates (Lefkowitz, 2007; Bylund, 2006). These experiments have thus
far resulted in 9 distinct AR subtypes. Interestingly, only the α1D-AR was cloned prior to
pharmacological characterization, making the identity of this receptor difficult to
confirm, initially (Bylund, 2006).
Subsequent analyses have found tissue-specific AR subtypes, such as the α1L-AR,
as well as potential subtypes which are pharmacologically distinct but deemed likely
variants of existing subtypes or which have not been successfully cloned, including the
α1C-AR and the β4-AR, respectively (Bylund, 2006; Granneman, 2001; Muramatsu et al.,
1998). This work recently culminated in the published crystal-structure of the β2-AR and
β2-AR-Gs complex by the laboratory of Brian Kobilka in 2007 and 2011, respectively, for
which he was awarded the Nobel Prize (Rasmussen et al., 2007; Rasmussen et al., 2011;
Westfield et al., 2011). While sequence similarities with rhodopsin and site-directed
mutagenesis studies had largely predicted some of the characteristics of the AR structure,
this represented an important milestone in our understanding of these G-protein coupled
receptors, especially of the ARs. Much of the work on the structure and signaling of
GPCRs was done be the Lefkowitz laboratory, which pioneered many of the techniques
for cloning of the ARs and found the structure of rhodopsin (Lefkowitz, 2013).
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Lefkowitz and Kobilka shared the 2012 Nobel Prize for Chemistry for their work
(Lefkowitz, 2013; Kobilka, 2013).
Epilepsy
Epilepsy is the 4th most common neurological disorder, with a lifetime incidence
probability of 1-in-26 (Hirtz et al., 2007; Shafer, 2015). No current therapies halt the
etiological progression of epilepsy (epileptogenesis), but rather antiseizure medications
are used as palliative care measures; these therapies are only 50-70% successful in
seizure control (Hirtz et al, 2007; Giorgi et al., 2004; Yin et al., 2013; Shafer, 2015).
Unfortunately, most current antiseizure drugs are associated with many side-effects on
memory and mood (Szilagyi, 2014; Petersen, 1998; ILAE, 2003). Most current epilepsy
therapies decrease global neuronal excitability and so these side-effects are inherent to
the very mechanism utilized to prevent, or limit, seizure occurrence.
Clinical Descriptions of Epilepsy
Epilepsy is diverse in clinical presentation but shares a measurable
electrophysiological manifestation. Epilepsy is hallmarked by recurrent and unprovoked,
transient disruptions of brain function by abnormal and excessive electrical activity
(seizures) (Fisher, 2017). The initial diagnosis criteria for epilepsy is the confirmation of
two or more seizures in a period of more than 24-hours; the observation of one seizure
with a determined high likelihood for subsequent seizures; or the diagnosis of a seizure
disorder. The second criterion is typically used in cases where a seizure is observed with
a known co-morbidity associated with acquired epilepsy, such as stroke or high fever
(Fisher, 2017).
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While epileptic seizures share a common underlying pathophysiology, the clinical
presentation or seizures is diverse and, in most cases, cause is poorly understood.
Roughly 60-70% of seizures are idiopathic, meaning the cause is unknown (AES, 2019).
Some factors likely influence predisposition to epilepsy include genetic, brain structure,
metabolic, and immune abnormalities and/or deficiencies (Wirrell, 2019). Additional
factors especially relevant to acquired epilepsy include brain trauma or infection.
Classically, seizures were categorized by a combination of two clinical
presentations, simple or complex and partial or generalized (Bancaud et al, 1981). These
terms describe the level of consciousness and location of activity during a seizure.
However, the clinical classifications for seizure types were updated in 2017 to include the
following types: focal onset, generalized onset, or unknown onset, with awareness or
impaired awareness (focal onset only), and by motor involvement (Fisher, 2017).
Generally, the changes in classification allow for more accuracy in clinical descriptions
and do not generally change the presentations being measured; those are the level of
consciousness and nature of the seizure.
Current Treatments and Antiepileptic Drug Discovery
Current antiepileptic therapies include pharmacological approaches, dietary
alterations, and electrical stimulation therapy. Currently, in the United States, there are
over 30 clinically-approved unique pharmacological agents (Vossler et al., 2018). While
there are new and emerging therapies, no current treatment is antiepileptogenic; rather,
current drugs are more accurately antiseizure drugs. The first known effective treatment
for epilepsy was the use of lithium. Though epilepsy was described in the earliest
medical texts (e.g. “The Sacred Disease” by Hippocrates) and suggested in even more
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ancient texts, it was only relatively recently that much progress had been made beyond
attempts at surgical ablation of the epileptic foci, or herbal remedies (Magiorkinis et al.,
2014; Wolf, 2014). Around the turn of the last century, the first known chemical
treatments with real success, the bromides (e.g. potassium bromide), were discovered to
be relatively reliable treatments for seizures. Bromides are no longer used as treatments
in epilepsy, due to a relative lack of efficacy and toxicity (Shorvon, 2009b)
The first breakthrough antiepileptic drug was phenobarbital in 1909 (Shorvon,
2009). Phenobarbital is a barbiturate which acts as a positive allosteric modulator of
ionotropic GABAA receptors to enhance the inhibitory actions of GABA. Phenobarbital,
and other barbiturates are extremely useful for treatment of status epilepticus and remains
useful to this day (Shorvon, 2009). However, barbiturates are notorious for pronounced
sedative side-effects, making their usefulness in everyday treatment limited.
The next major step in antiepileptic drug therapeutics came in 1939, from the
work of Merritt and Putnam who utilized drug-screening techniques by implementing
known chemoconvulsants in animal models and testing clinically-used drugs. The most
famous, phenytoin, a purified constituent of an earlier hypnotic drug was found to be
highly efficacious in screening and was quickly adopted for clinical use (Shorvon, 2009).
The mechanism of action for phenytoin is not well-understood, but is believed to enhance
inactivation of sodium channels (AES “Summary of Antiepileptic Drugs”). Phenytoin
and subsequent similar drugs were found to be useful in many types of epilepsies and was
not associated with as severe of sedative effects (Shorvon, 2009). Much of the next
decade or two saw the production of several new derivative drugs, some of which sought
to combine the molecular constituents of phenytoin and phenobarbital (Shorvon, 2009).
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The final major class of antiepileptic drugs still in use today are the
benzodiazepines (Wick, 2013). Like barbiturates, the benzodiazepines were found to be
effective for treatment acute seizure clusters and status epilepticus (Riss et al., 2008;
Shorvon, 2009b). Diazepam, and other benzodiazepines act similarly to the barbiturates,
but act directly upon GABAA receptors as agonists (Vossler et al., 2018). The
benzodiazepines were developed mainly as anxiolytics and sedatives, but were also found
to be useful in epilepsy (Shorvon, 2009b). This class of drugs presented an alternative to
barbiturates in acute epilepsy crisis. Notably, both the barbiturates and benzodiazepines
are associated with a high likelihood for dependency and abuse, so these classes of
antiseizure drugs are typically limited to acute crisis within the clinic.
Most recently implemented antiepileptic drugs are derived from, or similar to
phenytoin, barbiturates, and benzodiazepines (Vossler et al., 2018). Other potential
avenues have explored aspects of glutamatergic signaling, but have not found much
success (Shorvon, 2009b). Rather, most novel therapies, in recent years, have aimed at
reduction of side-effects, or combinatorial therapies to find greater treatment success in
drug-resistant epilepsies (Shorvon, 2009b). A recent novel avenue for epilepsy, as well
as pain, are the cannabinoids, specifically cannabidiol. This class of drugs has shown
exciting potential for treatment of several epilepsies. However, this is still an emerging
area of research and the mechanism of action is poorly understood. For example,
cannabidiol is not thought to interact through the known cannabinoid receptors, type 1 or
type 2 (Vossler et al., 2018).
Other than drug therapies, there remain several other therapies of interest in
epilepsy, including surgery, electrical stimulation, and diet. Brain surgery techniques
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have come a long way from the days of H.M. and temporal lobectomies (Augustinack et
al., 2014); current surgical ablation techniques implement intracranial EEG and MRI
(Chan et al., 2018; Englot et al., 2017). Surgery is still common in drug-resistant
epilepsies, especially in cases with well-defined epileptic foci (Choi et al., 2008; Engel et
al., 2003). Ketogenic diet is another alternative therapy, which has prevailed as an
epilepsy therapy since the 1930’s (Shorvon, 2009). The ketogenic diet replaces most
dietary carbohydrates with fats, encouraging a shift in metabolism towards ketogenesis
and the production of ketone bodies from fatty acids (Ulamek-Koziol et al., 2019;
Sampaio, 2016). The brain is able to use ketones as an effective alternative energy
source and seems to reduce seizure prevalence effectively for some patients; however, the
mechanism is poorly understood (Ulamek-Koziol et al., 2019; Sampaio, 2016). A final
established alternative antiepileptic therapy is vagus nerve stimulation. Vagus nerve
stimulation works by electrically stimulating the vagus nerve, sending impulses to several
sites within the brain (Ramani, 2008). Interestingly, as we will discuss in later chapters,
several studies have found that in-tact noradrenergic signaling is requisite for the efficacy
of both the ketogenic diet and vagus nerve stimulation (Giorgi, and Ramani, 2008).
A much more specific variant of electrical stimulation has recently gained traction
called responsive neurostimulation (Englot et al., 2017). The concept of this therapy is
similar to that of deep-brain stimulation used in diseases like Parkinson’s. Responsive
neurostimulation acts by sending electrical pulses when unusual activity is detected
(Englot et al., 2017; Jobst et al., 2017). The most cutting-edge among these stimulators
are programmed to specifically quench the activity with frequencies antidromic to the
main seizure frequency (Englot et al., 2017). Current pre-clinical research is attempting
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to develop closed-loop algorithms to predict seizure onset in real-time and provide
proactive prevention of seizure activity (Nagaraj et al., 2015; Krook-Magnuson et al.,
2015; Berenyi et al., 2012). Development of such predictive tools could be revolutionary
for focal seizure treatment, but may be extremely difficult for reasons described in the
next sections.
Neuron Physiology and Seizures
As previously mentioned, seizures are unprovoked, transient disruptions of brain
function by abnormal and excessive electrical activity. The brain is an electrical organ
which forms dynamic circuits locally and with the periphery (Swanson, 2008; Comin et
al., 2013; Buzsaki et al., 2004). The functional units of the brain, neurons, are cells which
conduct charges and generate an electrical potential via a precise balance of ions within
the cell. The electric potential is formed by an imbalance in charges, mostly of sodium,
potassium, and chloride, present within the cells and in the extracellular environment
(McCormick, 2008). Ion pumps actively curate an environment in neurons whereby the
intracellular environment contains more anions and less cations than the extracellular
environment (McCormick, 2008). The resulting imbalance of charge creates an electrical
potential, with the cell membrane serving as a selectively permeable barrier. The
resulting electrical potential makes the neuron polarized.
When a neuron becomes sufficiently depolarized by transient, selective opening
openings in the cell membrane, it discharges an electrical pulse during an event dubbed
the action potential (Hodgkin et al., 1952; Bean, 2007). Depolarization mostly occurs
due to the opening of ligand-gated ion channels, while voltage-gated ion channels
dominate during the action potential (Bean, 2007). Generally, this electrical potential is
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carried from the cell body (soma) of the neuron to the axon terminal(s), where it
stimulates the release of neurotransmitters. Prototypic neurons release glutamate or γaminobutyric acid (GABA) to excite or inhibit the next cell(s) in the circuit, respectively
(McCormick, 2008). Within a neural circuit, there exists both excitatory and inhibitory
neurons. Excitatory neurons carry information, while inhibitory neurons regulate the
conveyance of the information (Kepecs et al., 2014).
During a seizure, there is an imbalance between excitatory and inhibitory
neuronal activity. During a seizure, excitatory, or glutamatergic, neurons are not
correctly inhibited, and thus, there is excessive and abnormal electrical activity within the
circuit (Traub et al., 2014; Bernard et al., 2000; Stief et al., 2007). Initiation of seizure
activity is poorly understood, but brain regions with highly recurrent circuitry, such as the
hippocampus, are common areas of seizure foci. Feedback pathways, such as recurrent
synapses, are common within the brain, but in this context the feedback causes excitation
of neighboring cells, rather than regulatory inhibition. Within a recurrent circuit
electrical signals are amplified as a depolarizing neuron excites neighboring neurons ( Le
Duigou et al., 2014; Traub et al., 1982; Miles et al, 1983; Miles et al., 1986).
The recruitment phase of a seizure is also a poorly understood phenomenon but
may involve non-synaptic conduction (i.e. action at a distance) from growing electrical
fields (Weiss et al., 2013; Isaev et al., 2012; Zhang et al., 2014). The inability of the
inhibitory circuitry to cease, or limit, recruitment leads to the eventual overwhelming of
the inhibitory circuitry (Shevon et al., 2012; Trevelyan et al., 2006; Steif et al., 2007).
One line of thinking posits that this likely because excitatory neurons outnumber
inhibitory neurons by as much as a factor of 30, and functionally, by a factor of about 10;
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meaning that inhibitory circuitry may be overwhelmed when typically-silent neurons
become recruited to depolarize, such as in a seizure (Shoham et al., 2006; Ovsepian,
2019; Miles et al., 1987).
One may wonder why the brain is prone to seizures in the first place. In most
cases (6-out-of-10), seizures are idiopathic, meaning the cause of is not associated with
any obvious structural or functional abnormalities (Schachter). It has been suggested that
even normal brain operation occurs in a highly entropic state, meaning that even minute
dysfunction can lead to profound consequences (Beggs et al., 2008; Beggs et al., 2012;
Roberts et al., 2015; Hesse et al., 2014). This highly chaotic and energetic system is
typified by well-known neural oscillation patterns, sometimes known colloquially as
brain waves or EEG patterns (Werner, 2007; Poil et al., 2008; Buzsaki, et al 2004).
Normal brain oscillation patterns exemplify the necessity for signal amplification in a
dynamic brain, but the commonality of seizures demonstrates the fragility of such a
system.
Noradrenergic System in Epilepsy
Studies over several decades have revealed that norepinephrine exhibits
antiepileptic properties, both in vitro and in vivo. Further, ablation of noradrenergic
fibers exacerbates several models of epilepsy (Giorgi et al., 2004). The literature
suggests that noradrenergic participation is especially efficacious in progressive models
of epilepsy, such as kindling (Cochran, 1980; McIntyre, 1981, 1986). The effect of NE in
epilepsy models was first assessed by methods for chemical ablation on noradrenergic
neurons in the locus coeruleus; These approaches included direct injection of the nonselective catecholminergic neurotoxin 6-hydroxydopamine into the locus coeruleus, or
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alternatively, systemic administration of the noradrenergic-selective neurotoxin N-(-2chloroethyl)-N-ethyl-2-bromobenzylamine (Giorgi, 2004). These studies characterized
the loss of brain norepinephrine in several epilepsy models. The conclusions drawn from
these studies were robust and recognized NE as possessing antiepileptic potential;
however, due to limitations of the methodology, these studies did little to elucidate the
receptor subtypes mediating these effects (Mishra, P, 1994; Arnold, P., 1973; McIntyre
D., 1979). These experiments also provided great insight into the importance of the locus
coeruleus noradrenergic fibers; because these methods largely left lateral tegmental
noradrenergic fibers in-tact, this revealed that the locus coeruleus fibers were the
predominant fibers responsible for the antiepileptic effects of NE (Giorgi, 2004;
Weinshenker et al., 2004) Experiments stimulating the release of NE, or blocking
reuptake, found the opposite effects of the ablation studies; thus, supporting the theory
that NE is an antiepileptic neurotransmitter (McIntyre, 1982; Jimenez-Rivera, 1986).
Studies have been done to attempt to elucidate the receptor subtypes responsible
for the antiepileptic effects of NE, but current adrenergic ligands lack subtype selectivity
and/or do not readily cross the blood-brain barrier (Weinshenker et al., 2004). This
review looked extensively through the literature and found that no one receptor class is
solely antiepileptic or proepileptic. The authors attribute the conflicting findings to the
lack of ligand specificity and likely differences in the roles of subtypes within the AR
classes.
This aspect of elucidating the AR subtype roles is explored further in Chapter II.
Briefly, we have developed a system for pharmacologically isolating AR subtypes by
utilizing combinations of antagonists and agonists in hippocampal slices. A major novel
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implementation of this research was the utilization of AR subtype knockout mice to more
confidently assess contributions of a particular subtype of interest, the α1A-AR. Our
interests in the α1A-AR, besides antiepileptic potential, are based on findings which
suggested that, in healthy mice, constitutive α1A-AR activation results in increased
learning and memory, improved mood, and increased synaptic plasticity (Doze et al.,
2011). Thus, α1A-AR activation could prove dually beneficial for epilepsy patients, since
epilepsy is associated with elevated incidence in mood; and because most current
therapies are detrimental to memory formation, general cognitive function, and can
exacerbate mood abnormalities.
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CHAPTER II
α1A-AR, BUT NOT α1B-AR, ACTIVATION ATTENUATES EPILEPTIFORM

FREQUENCY AND RECEPTOR KNOCKOUT EXACERBATES
EPILEPTIFORM FREQUENCY
Introduction
As previously discussed, noradrenergic fiber ablation in rodent seizure models led
to the conclusion that norepinephrine confers an antiepileptic phenotype. Additionally,
both the ketogenic diet and vagus nerve stimulation therapies rely upon an intact
noradrenergic system (Giorgi et al., 2004). Such an apparent role in epilepsy raised the
question of which AR subtypes confer these antiepileptic effects and whether they can be
selectively targeted.
Previous studies within our laboratory have shown that α1-AR activation increases
the excitatory potential of interneurons, including a direct depolarization of the
membrane potential of interneuron subpopulations (Bergles et al. 1996; Hillman, et al.,
2009). This research also suggested that the increased activity of the interneurons,
ostensibly achieved by decreasing basal potassium conductance and increasing inwardly
rectifying hyperpolarization-activated conductance, was powerful enough to decrease the
excitability of pyramidal neurons in the hippocampus (Bergles, 1996). The latter study
by Hillman suggested the importance of the α1A-AR to this effect and that these effects
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carry to a broader circuit-level effect, to increase hippocampal inhibitory tone
(Hillman 2009). Attempts to identify AR subtypes in neuronal populations to elucidate
the physiological mechanism underlying these actions has been largely limited to
functional isolation via genetic and pharmacological manipulation; currently, no selective
antibodies exist for targeting the α1A-AR for immunofluorescence identification (Jensen
et al., 2009). Further, we have found that overexpressed reporter-tagged α1A-AR mutant
mice show expression in cell types where no function can be found (Papay et al., 2006;
Hillman et al., 2005; Hillman et al., 2007).
In this study, we investigated the specific role of α1A-AR activation in
epileptiform frequency by utilizing a combination of α1-AR subtype knockout mice and
selective ligands. The low-magnesium model of epileptiform burst generation was used
in this study to study the effect of α1A-AR stimulation on epileptiform burst frequency in
the mouse hippocampus. Reducing magnesium results in the loss of magnesium-block to
NMDA glutamate receptors. This alteration results in the generation of rhythmic,
seizure-like bursts associated with an overwhelming of inhibitory signaling (Trevelyan et
al., 2006). In order to circumvent the limitations of previous pharmacological
characterizations, we transitioned our research from rats to mice and implemented the use
of genetically modified knockout mice. We investigated the effect of α1-AR activation
using the selective agonist, phenylephrine, in normal control mice, as well as knockout
mice lacking functional expression of either the α1A-AR or α1B-AR. Also, we assessed
the potential for differential effects dependent upon the agonist activating the α1A-AR,
using pharmacological isolation techniques. Finally, we present a previously unknown
phenomenon suggesting that loss of α1A-AR expression leads to exacerbation of
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hippocampal epileptiform frequency. We discuss the importance of these findings and
the potential to explain phenomena seen in vivo.
Materials and Methods
Reagents
Sodium chloride, calcium chloride, potassium chloride, dextrose, sodium
bicarbonate, sodium pyruvate, and sodium phosphate monobasic were from Fisher
Scientific. (-)-Phenylephrine hydrochloride, timolol maleate, (-)-epinephrine-(+)bitartate, and were from Sigma Aldrich. Atipamezole hydrochloride, picrotoxin, and
cirazoline hydrochloride were from Tocris Bioscience. Magnesium sulfate and sodium
L-ascorbate were from JT BAKER and Pfaltz and Bauer, respectively.
Animal Use
Mice were housed in an AAALAC-accredited facility at the University of North
Dakota. All experiments involving mice were performed under IACUC-approved
protocols. C57BL/6J mice were obtained from Jackson Laboratories. Knockout
background mice (in-bred C57BL/6 mice), α1A-AR knockout mice, and α1B-AR
knockout mice were generously provided by the lab of Dianne Perez at the Cleveland
Clinic Foundation (Lerner Institute, Cleveland, OH).
α1A-AR Knockout Mouse Generation

α1A-AR knockout reporter mice were generated as previously described (Rokosh
et al., 2002). Briefly, a plasmid vector containing 1.1 Kb from the 5’ arm and 6.5 Kb
from the 3’ arm, sequence retrieved from the 129/SvJ genomic library, targeted portions
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of critical exon 1 and the adjacent intron for excision from the α1A-AR gene. This vector
also contained a LacZ operon and conferred resistance for neomycin.
The plasmid vector was transfected into RW-4 129/SvJ embryonic stem cells
using electroporation. Positive transfections were identified with neomycin resistance.
Positive cells were cultured and analyzed for correct insertion. A small fraction of
transfected samples contained the correct insertion with no additional random insertions.
These embryonic stem cells were subsequently chosen for insertion into C57BL/6
blastocysts. Blastocysts were implanted into a 129SvJ x FVB/N female; subsequently,
pups were assessed for germ-line expression of the correct mutation.
Finally, heterozygous mutant mice were bred up and back-crossed with C57BL/6
and FVB mice for several generations. These mice are considered congenic to C57BL/6
mice, the stain for which we utilize as “normal” controls (Simpson PC, 2006).
α1B-AR Knockout Mouse Generation

The α1B-AR knockout was previously generated as described in a similar fashion
to the α1A-AR knockout mouse (Cavalli et al., 1997). A portion of exon 1 was replaced
with a vector conferring neomycin resistance. Blastocysts were selectively injected into
pseusopregnant female 129Sv x C57BL/6J mice. Mice were subsequently back-crossed
for several generations and is congenic to the C57BL/6 background strain (Simpson,
2006).
Hippocampal Slice Preparation
Isoflurane (Isothesia, Henry Schein Animal Health) was used to deeply
anesthetize mice, which were then decapitated. The brain was quickly removed and
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immediately placed in ice-cold artificial cerebrospinal fluid (aCSF) for dissection,
containing (in mM): choline chloride 110, dextrose 25, sodium bicarbonate 25,
magnesium sulfate 7, sodium pyruvate 3.1, sodium ascorbate 11.6, calcium chloride 0.5,
potassium chloride 2.5, sodium phosphate monobasic 1.25.
Hippocampi were isolated and sectioned into 450 µm coronal slices. Upon
sectioning, slices were immediately transferred to 33-35oC aCSF, containing (in mM):
Sodium chloride 119, dextrose 11, sodium bicarbonate 26.2, magnesium sulfate 1.3,
calcium chloride 2.5, potassium chloride 5, sodium phosphate monobasic 1. After 30
minutes, slices were removed from incubation and allowed to equilibrate at room
temperature for at least an additional 60 minutes. All solutions were continually perfused
with 95% O2/ 5% CO2.
Electrophysiological Local Field Potential Recordings
Extracellular local field potential recordings were performed using a borosilicate
glass pipet, pulled using a Narishige vertical puller. Pipettes contained a silver/silverchloride recording filament, and were filled with 3 M sodium chloride. Freshly sanded
silver wire was chloride to minimize the rate of oxidation and provide minimal baseline
drift during recording (Grubbs et al., 1983). Recording electrodes were placed deep into
the stratum pyramidale of the CA3 region of the hippocampus, where epileptiform bursts
were measured in changes of electrical potential at the electrode. Specifically, the border
of the CA3a-b sub-regions were targeted. Recordings were measured in bridge-clamp
mode by an Axoclamp 2B data acquisition and amplification system (Axon Instruments),
set to 10x gain. Signals were further amplified by a Brownlee Precision 440 amplifier
(AutoMate Scientific), set to 100x gain. Signals were transformed from direct current to
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alternating current by a DigiData 1322a digitizer (Axon Instruments). Signals were
recorded using pClamp 9 (Axon Instruments) software package. Line transmission
interference was selectively reduced on-line with a dedicated band-pass filter unit
(Digitimer). Extraneous environmental interference was reduced or eliminated via
Faraday cage and strategic grounding procedures. Vibration was isolated minimized by
an air table (TMC).
Epileptiform Activity Generation in Hippocampal Slices
Individual slices were transferred to a recording chamber filled with aCSF bath
solution flowing at a rate of 4-5 mL/min. Bath solution was input to the recording
chamber via gravity-driven flow, which was regulated by a common intravenous therapy
flow regulator. Bath flow rate was determined by hand-timed measurements of solution
reservoir volume. Epileptiform activity was generated using aCSF with no magnesium
added and increased potassium concentration, 5 µM adjusted from 2.5 µM. If slices did
not produce regular synchronized activity within 45 minutes after introduction of no
magnesium aCSF slices were determined to be non-responsive and discarded. Further,
after generation of regular epileptiform activity slices were recorded for baseline activity
for at least 30 minutes, or until the rate of spiking had become stable. Regularity was
determined by comparisons of burst frequency at 5-minute intervals.
Dose-Response and Pharmacological Manipulation
Characterization of receptor response was achieved by the application of various
AR agonists at increasing dosages. Specifically, initial experiments (data not shown)
were performed to determine likely efficacious range. After initial determination of
efficacious range, and collection of baseline epileptiform burst frequency, increasing
25

concentrations of drug were added to the bath solution in 8-minute intervals. This
interval was chosen based on time-course interval studies of time to maximal effect, with
additional time added to compensate for dead volume of bath solution inlet lines. Drug
concentration was increased at half-logarithmic increases based on the assumption that
the generated dose response relationship would be sigmoidal on a logarithm-transformed
axis for drug concentration. This logarithm-transformed sigmoidal curve fit is the most
common dose-response relationship observed in biology and is modeled from massaction equations which describe the non-linear interaction probabilities between
dissimilar molecules due to volume and molecule prevalence (i.e the probability of
interaction between dissimilar molecules is negligible until concentrations of each are
sufficiently high, whereupon interactions suddenly become much more common)
(Kenakin, 2016; Guldberg et al., 1879).
We evaluated dose-response relationships for both endogenous AR agonists,
norepinephrine and epinephrine, as well as the α1-AR specific agonist, phenylephrine
(Furchgott, 1967). Comparison of dose-response curves allowed us to assess the relative
efficacy of phenylephrine to the full agonist endogenous ligands norepinephrine and
epinephrine. Comparison of α1-AR specific effects were made possible by constant
blockade of α2-ARs and β-ARs by constant bath application of saturating concentrations
of atipamezole and timolol, respectively. Specific contributions of α1-AR subtypes found
in the central nervous system were investigated by generating phenylephrine doseresponse curves in hippocampal slices from α1A-AR and α1B-AR knockout mice.
Contribution of GABAergic signaling was assessed in phenylephrine dose-response
experiments in the presence of 100 µM picrotoxin, a GABA-A receptor blocker.
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Analysis
Epileptiform bursts were identified in Clampfit 10 by threshold and waveform
analysis, then exported to Microsoft Excel 2016 or Google Sheets for sorting of
epileptiform spikes. Spikes were sorted into 150-second or 300-second bins, depending
on the baseline epileptiform frequency, to allow for enough data collection to
differentiate epileptiform frequency changes of at least a 10%. The last bin associated
with each concentration was then exported for further analysis. Only the last bin was
selected to accurately assess the effects of each dose, allowing adequate time for
perfusion and receptor signaling, while also providing adequate data for normalization of
outliers. Graphs and dose-response curves were prepared with GraphPad Prism 7.x or
8.x. The dose-response relationship for these experiments was generated by a non-linear
regression analysis. These data were best fit using [Agonist] vs. response (threeparameters) Dose-Response – Stimulation non-linear regression parameters. Predicted
values reported from the non-linear regression functions include the drug concentration
of half-maximal response (EC50), or potency, and maximum drug response, or efficacy.
The values shown within this chapter are typically shown in figures as negative
responses. However, these responses are mediated by agonists and would not be reported
correctly by antagonist dose-response values, such as an IC50. While potentially counterintuitive, this representation provides the reader with a clear representation of the nature
of the effect (i.e. excitation of receptors results in decreased epileptiform burst frequency.
Any relevant statistical tests are discussed within the text, as appropriate.
Results
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Agonist-mediated α1-AR Stimulation Attenuates Mouse Hippocampal CA3 Slice
Epileptiform Frequency in a Magnesium-depletion Model of Seizure-like Activity
Magnesium is an important regulator of neural excitability. Magnesium ions are
divalent cations, which imitate many chemical properties of calcium. In normal
cerebrospinal fluid (CSF) magnesium concentrations are between 1-2 mM and block Nmethyl-D-Aspartate (NMDA) glutamatergic channels. When magnesium is removed
from artificial CSF (aCSF) the result is dysregulated glutamatergic channel activity and
spontaneous neuronal hyperactivity. At room temperature, spontaneous epileptiform
bursts from mouse hippocampal CA3 area occurred at regular intervals with a mean
frequency of approximately 0.1 Hz (Fig. 3A). Our experiments investigated the effects of
AR agonists on the epileptiform burst frequency, which we measured as a function of the
baseline frequency (Fig. 3B). A dose-response curve was utilized to characterize the
potencies and efficacies of agonists by plotting the frequency of the final time bin
associated with each dose and performing a non-linear regression curve fit analysis (Fig.
3C).
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Figure 3. Epileptiform Activity Recording and Dose-Response Relationship
Analysis. (A) Example electrophysiological hippocampal field activity recording trace
of epileptiform bursts and (outset) image of hippocampal slice showing recording
electrode in the stratum pyramidale of the CA3a subregion. (B) Example graphic
illustrating the plotting of time and number of spikes into discrete bins, with tracking of
dose applied during each time. (C) Example graphic illustrating the transformation of the
time axis to concentration of ligand (dose) and the non-linear curve fit to the last discrete
bin associated with each dose. Note that the typical dose-response curve is sigmoidal on
a logarithmic scale and is customary to present it as such.
Characterization of Endogenous and Synthetic AR Agonists Effects on
Hippocampal CA3 Epileptiform Burst Frequency
We investigated the potential of endogenous and synthetic AR agonists to alter
spontaneous epileptiform burst frequency by assessing dose-response relationships for
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several agonists. NE (Fig. 4A) exhibited a slightly higher maximum attenuation than
Epinephrine (EPI) (Fig. 4B), with efficacies estimated to be 16.88±2.87% (n=5 Slices)
and 12.78±2.49% (n=5 Slices), respectively. EPI exhibited a slightly higher potency,
1.85 µM, than NE, 6.29µM, but as predicted by binding values they were within the
same order of magnitude for the α1A-AR. Additionally, we investigated the α1-ARselective agonist, phenylephrine (PE). The efficacy value for PE, 16.08±1.89% (n=5
Slices), was similar to the endogenous catecholamines and suggested that our
pharmacological blockade of α2-AR and β-AR contributions was functioning as expected.
The potency for PE, approximately 2.31 µM, was similar to NE and EPI. In the presence
of α2-AR and β-AR blockers, and with evidence from α1-AR-selective agonist, PE, there
is an apparent attenuation of epileptiform burst frequency mediated by α1-AR activation.
Although it has been done previously in rats, we also assessed the contributions of
GABAergic signaling to the observed effects by investigating phenylephrine response in
the presence of 100 µM picrotoxin. Picrotoxin is potent GABAA receptor blocker and
common chemoconvulsant used to generate epileptiform burst activity in disinhibitory
animal models of epilepsy. We observed an abolishment of phenylephrine-mediated
decreases in epileptiform burst frequency in the presence of 100 µM picrotoxin (n=2
slices) (Fig. 5). This data suggested that phenylephrine-mediated effects are GABAdependent, which had been shown previously in rat hippocampus (Hillman et al., 2009).
Additionally, we noted that at all doses of phenylephrine the response measured was
greater than the baseline frequency. However, this is likely representative of inherent
differences in baseline epileptiform frequency from the addition of picrotoxin, rather than
effects representative of phenylephrine-mediated alterations. Unfortunately, we did not
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collect an additional baseline frequency measurement following introduction of
picrotoxin to the low-magnesium aCSF.
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Figure 4. Dose-Response Relationships of Endogenous and Synthetic Agonists. (A)
Epileptiform burst frequency in response to increasing doses of the endogenous agonist
epinephrine. (B) Epileptiform burst frequency in response to increasing doses of the
endogenous agonist norepinephrine. (C) Epileptiform burst frequency in response to
increasing doses of the α1-AR-selective agonist phenylephrine. All dose-response curves
are normalized to the baseline epileptiform burst frequency.

Figure 5. Dose-Response Relationships Phenylephrine in the Presence of Picrotoxin.
Epileptiform burst frequency in response to increasing doses of the α1-AR-selective
agonist phenylephrine in the presence of 100 µM picrotoxin. Dose-response curve was
normalized to the baseline epileptiform burst frequency without picrotoxin.
α1A-AR, but not α1B-AR, Knockout Abolishes α1-AR Activation-mediated
Attenuation of Hippocampal CA3 Epileptiform Burst Frequency
We further assessed the nature of the α1-AR activation-mediated attenuation of
epileptiform burst frequency using α1A-AR and α1B-AR constitutive knockout mice. In
the presence of α1-AR-selective agonist, PE, we observed that α1-AR activation-mediated
attenuation of epileptiform burst frequency was completely abolished in hippocampal
slices from α1A-AR knockout mice (efficacy= N.D., n=8 Slices) (Fig. 6A). Conversely,
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PE attenuation was similar to wild-type control slices in slices from α1B-AR knockout
mice (efficacy=16.83±2.23%, n=12 Slices) (Fig. 6B). Interestingly, the potency was
approximately an order of magnitude weaker, 21.94 µM, than PE in slices from wild-type
control mice; however, it is worth noting that there was variability in all potency
estimates and the value for this group was estimated from several partial dose-response
curves. Together, these experiments showed that α1A-AR knockout results in a complete
abolishment of α1-AR activation-mediated attenuation of hippocampal epileptiform burst
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frequency, whereas hippocampal slices from α1B-AR knockout mice exhibited little
variation from effects observed in slices from wild-type control mice.
A

B

Figure 6. Dose-Response Relationships of Phenylephrine in Hippocampal Slices
from α1-AR Subtype Knockout Mice. (A) Epileptiform burst frequency in response to
increasing doses of phenylephrine in hippocampal slices from α1A-AR knockout mice.
(B) Epileptiform burst frequency in response to increasing doses of phenylephrine in
hippocampal slices from α1B-AR knockout mice. All dose-response curves are
normalized to the baseline epileptiform burst frequency.
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Hippocampal Slices from α1A-AR knockout mice, but not α1B-AR knockout mice,
Exhibit Higher Baseline Epileptiform Burst Frequency
We observed an interesting phenomenon when testing dose-response relationships
in hippocampal slices from wild-type control and α1-AR subtype knockout mice. The
baseline frequencies for each mouse strain were determined after spontaneous burst
frequencies were determined to be stable for at least 15-minutes (Fig. 7). ANOVA
(P=0.0064) suggested that there was a significant difference in the baseline frequencies
between slices from wild-type controls, α1A-AR knockouts, and α1B-AR knockouts.
Dunnett’s Multiple Comparisons (P=0.0068) test revealed that the baseline frequency of
hippocampal slices from α1A-AR knockout mice (0.16±0.01 Hz, n=12 Slices) was
significantly higher than the baseline frequency of wild-type control slices (0.10±0.01
Hz, n= 11 Slices). In contrast, no significant difference (P=0.8416) was observed
between the baseline epileptiform burst frequency of hippocampal slices from wild-type
control mice and slices from α1B-AR mice (0.11±0.02 Hz, n=13 Slices). The mean
difference in hippocampal epileptiform burst baseline frequencies from wild-type control
mice and α1A-AR knockout mice (0.60±0.02 Hz) is equivalent to a baseline frequency
158.7% greater in slices from α1A-AR knockout mice than that of slices from wild-type
control mice.
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Figure 7. Comparison of Baseline Epileptiform Burst Frequencies in Hippocampal
Slices from Control and α1-AR Subtype Knockout Mice. Baseline epileptiform burst
frequency in each mouse line as observed from the Hippocampal CA3 region. Statistical
analyses are representative of one-way ANOVA and Dunnett’s post-hoc multiple
comparisons test. Statistical significance is represented as follows: No statistical
significance (n.s.), P < 0.05 (*), P < 0.01 (**), P < 0.001 (***).
Discussion
Our results have produced several exciting findings: 1) α1-AR activation by
several AR agonists elicited a moderate decrease in epileptiform frequency from the
mouse hippocampus; 2) These effects were observed within the hippocampal CA3
region; 3) knockout of the α1A-AR abolished the previously observed phenomenon, while
α1B-AR knockout resulted in no observable difference from AR activation in
hippocampal slices from wild-type control mice; 4) α1A-AR knockout results in a
significant increase in baseline hippocampal epileptiform burst frequency.
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An important observation and potential caveat to our results, is that we
consistently observed a positive baseline drift at sub-efficacious doses and in α1A-AR
knockout mice, which may suggest that our dose-response relationships are artificially
less-efficacious than that should be. A potential remedy for this observation would be to
implement baseline observations between doses or to observe each dose-response
individually. However, the first remedy would require the assumption that there is no
desensitization to the agonist, an unlikelihood. The second remedy would be wasteful in
terms of mice needed. Since these baseline drift is on the order of 0-5%, over time, a
third potential remedy would be to normalize the baseline over time with by performing
no agonist controls for several hours and implementing this normalization factor prior to
the time-dose transformation step in our analysis. Here, it was our preference to present
the data with no normalization and instead allow the reader to make their own
assessment.
These results were especially interesting within the context of previous
experiments. Previously, the effect of α1-AR activation was only known to decrease
epileptiform burst frequency in the rat hippocampus. Our findings support our previous
work and show that the characteristics of α1-AR activation in the epileptic hippocampus
are not limited to the rat, increasing the robustness and increasing the translational
potential of these results. Additionally, our findings present the first time that this α1-AR
antiepileptic effect has been observed in the CA3 region. All previous studies focused in
the CA1 region of the hippocampus. This further suggests a robust phenomenon. Out
implementation of hippocampal slices from α1-AR subtype knockout mice allowed us to
investigate the specific contributions of the subtypes with known expression in the central
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nervous system, the α1A-AR and α1B-AR. From our experiments with these knockout
strains, we concluded that the α1A-AR is the predominant α1-AR subtype responsible for
previously observed antiepileptic characteristics. While previous experiments by
Hillman suggested this finding with α1A-AR-selective antagonists, the unpredictable
nature of AR cross-reactivity left doubt. Perhaps, the most unexpected and novel finding
from this study were our results which showed that α1A-AR knockout increased the
baseline epileptiform burst frequency by over 1.5-fold. This finding is especially exciting
because it suggests that α1A-AR knockout results in a significant compromise of the
circuitry responsible for preventing epileptiform activity within the hippocampus.
Interestingly, this finding may suggests a potential mechanism and method for
elucidating our observations discussed in the next chapter.
To our knowledge, very few studies have implemented AR knockout mice to
study receptor subtype contributions in models of epilepsy. A notable exception is the
work by Pizzanelli and colleagues, which identified that loss of α1B-AR expression
resulted in significant protective effects against the onset of chemoconvulsant-induced
seizures, in mice. While our own results do not support a role for the potential
proconvulsant effects of α1B-AR activation, it cannot be ruled out. In fact, the results by
Pizzanelli are extremely compelling and, taken together, may support a hypothesis for a
compensatory effect in α1B-AR knockout mice. However, no reciprocal increase in α1AAR or α1B-AR was observed in either receptor knockout mouse strain, as would be
expected if there were a compensatory mechanism at work. Thus, the exact mechanism
of α1A-AR and α1B-AR contributions remains unclear, but both studies utilizing knockout
mice have revealed potential anticonvulsant properties of the α1A-AR (in vivo findings
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discussed in subsequent chapters) and a proconvulsant or no role for the αB-AR in
epilepsy models. Further, these experiments show exciting progress towards
understanding the specific contributions of AR subtypes to the demonstrated antiepileptic
nature of NE.
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CHAPTER III
α1A-AR ACTIVATION INCREASES THE LATENCY TO EPILEPTIC SEIZURE

EMERGENCE, WHILE RECEPTOR KNOCKOUT INCREASES PREVALENCE
OF SPONTANEOUS AND RECURRENT EPILEPTIC SEIZURES
Introduction
While previous research in our laboratory and the results from Chapter 2 provide
ample evidence that α1A-AR activation, specifically, is capable of attenuating
epileptiform burst frequency in hippocampal slices, measured in both CA3 and CA1
regions, of both mice and rats, there has been little investigation into the translational
potential of these findings. To investigate the effects of α1A-AR activation on seizures in
vivo, we set out to establish a model of chemoconvulsant-induced seizures, utilizing the
sea weed-derived glutamate analog, kainic acid, a potent glutamatergic kainic acid
receptor agonist. Importantly, kainic acid induces seizures by creating a hyperexcitatory
environment, rather than altering inhibitory circuitry (Ben-Ari et al., 2000). The
mechanism of this chemoconvulsant was important because we have hypothesized that
the effects of α1A-AR on seizure threshold is due to its excitation of inhibitory
interneurons. Thus, ablation of inhibitory circuitry would likely mask the efficacy of
receptor activation.
The experiments herein, utilized relatively high doses of kainic acid to induce a
state of acute status epilepticus. While our previous results suggest that NE antiepileptic
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characteristics are most efficacious in progressive (chronic) insult models of epilepsy,
we wanted to investigate the effects of α1A-AR activation in an acute seizure model. Our
reasoning for this choice was an effort to maintain consistency with the experiments
performed in hippocampal slices and we were interested in the robustness of any
observed effects. Our hippocampal slice model of epilepsy is an acute model, in that
magnesium deprivation is constant throughout our experiment and that the short-term
nature of our recordings provides little time for changes to hippocampal circuitry, as
would be expected in chronic seizure/epilepsy models.
In addition to kainic acid-induced seizures, we investigated anecdotal and initial
investigations into spontaneous seizures observed in α1A-AR knockout mice.
Unfortunately, this propensity for seizures means that the α1A-AR knockout mice are a
poor candidate for induced seizure models. Instead, we observed α1A-AR knockout mice
over a period of 48-hours to investigate several lingering questions about these
spontaneous seizures; do α1A-AR knockout mice only exhibit seizures when exposed to
aversive, stressful stimuli (such as handling or bright, open spaces)? Can these seizures
be considered chronic, possibly indicating α1A-AR knockout mice as a candidate epilepsy
model? What are the nature of these seizures? We make observations of these questions
and we establish a protocol for electroencephalographic characterizations of seizures in
these mice.
Our investigation of α1A-AR activation in kainic acid-induced status epilepticus is
an important step towards evaluating the translation potential of an α1A-AR antiepileptic
therapy. Further, our use of kainic acid, other than being advantageous, was very
purposeful. Kainic acid is a versatile chemoconvulsant that can be used in low doses to
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induce a model of temporal lobe epilepsy which exhibits some similarities to kindlinginduced epilepsy; a model which has shown ARs to be particularly efficacious (Tse et al.,
2014; Hellier et al., 1998).
The results presented herein lay the framework for future investigations of the
α1A-AR antiepileptic modality in chronic models of epilepsy. However, for the first time,
these results directly elucidate the translational potential of our findings in hippocampal
slices in vivo and suggest applicability of α1A-AR activation characteristics outside of the
hippocampus. Additionally, our investigations of the spontaneous seizures exhibited by
α1A-AR knockout mice may suggest that this receptor subtype may be a viable and novel
animal model of epilepsy.
Materials and Methods
Animal Use and Drug Treatment
Mice were housed in an AAALAC-accredited facility at the University of North
Dakota. All experiments involving mice were performed under IACUC-approved
protocols. C57BL/6J mice were obtained from Jackson Laboratories. Knockout
background mice (in-bred C57BL/6 mice) and α1A-AR knockout mice were generously
provided by the lab of Dianne Perez at the Cleveland Clinic Foundation (Lerner Institute,
Cleveland, OH).
All kainic acid experiments used male and female C57BL/6J mice, aged 80-95
days. Following general health assessments, mice were randomly and evenly distributed
to into untreated control or treated groups. In treatment groups, mice were administered
40µM cirazoline hydrochloride (Tocris Bioscience), in drinking water, ad libitum.
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Importantly, treated drinking water was prepared using only water from the same source
as untreated mice. Cirazoline treatment continued for a period of 4-weeks prior to
experimentation.
α1A-AR Knockout Mouse Generation

α1A-AR knockout reporter mice were generated as previously described (Rokosh
et al., 2002). Briefly, a plasmid vector containing 1.1 Kb from the 5’ arm and 6.5 Kb
from the 3’ arm, sequence retrieved from the 129/SvJ genomic library, targeted portions
of critical exon 1 and the adjacent intron for excision from the α1A-AR gene. This vector
also contained a LacZ operon and conferred resistance for neomycin.
The plasmid vector was transfected into RW-4 129/SvJ embryonic stem cells
using electroporation. Positive transfections were identified with neomycin resistance.
Positive cells were cultured and analyzed for correct insertion. A small fraction of
transfected samples contained the correct insertion with no additional random insertions.
These embryonic stem cells were subsequently chosen for insertion into C57BL/6
blastocysts. Blastocysts were implanted into a 129SvJ x FVB/N female; subsequently,
pups were assessed for germ-line expression of the correct mutation.
Finally, heterozygous mutant mice were bred up and back-crossed with C57BL/6
and FVB mice for several generations. These mice are considered congenic to C57BL/6
mice, the stain for which we utilize as “normal” controls (Simpson PC, 2006).
Seizure Generation
Following a 30-minute cage acclimation period, seizures were generated in mice
following intraperitoneal injection of the chemoconvulsant kainic acid (Tocris
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Bioscience), at 25 or 35 mg/kg. The doses we used, 25 mg/kg and 35 mg/kg, resulted in
about 40% mortality and greater than 70% mortality, respectively, across all treatment
groups. Additionally, 35 mg/kg kainic acid resulted in nearly all mice reaching severe
seizure stages, including generalized tonic-clonic seizures. Due to its relatively short
half-life in solution, kainic acid was prepared fresh daily, several hours prior to
experiments, at a stock concentration of 2.0 mg/mL, in 1x phosphate buffered
saline. Kainic acid solutions were prepared from the same chemical stock batch for each
experiment to maintain maximal consistency. Mice were observed for a total of 2-hours
post-injection.
Behavioral Scoring
Seizures were scored according to a modified Racine’s scale for characterizing rodent
seizures. Briefly, seizure activity was scored grades 1-6 according to the following
criteria: (1) Sudden and prolonged cessation movement with orofacial spasms, (2)
prolonged and exaggerated hunched posture with head bobbing, (3) emergence of
pronounced forelimb clonus, (4) emergence of forelimb clonus and rearing, (5)
progression to rearing and falling, (6) loss of postural control with full body involvement
tonic-clonic activity. Grade 1 activity was not characterized in experiments without
electroencephalographic confirmation. Seizure activity was recorded for later analysis.
Videos were blinded by persons uninvolved with the experiments and unaware of the
treatment groups for scoring by a trained observer.
Video Synchronized Electroencephalography
Kainic acid response was further characterized using video-EEG. Briefly, a fourchannel EEG head-stage (Pinnacle Technologies) was surgically attached to the mouse
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skull (Fig. 8). Leads were placed strategically to capture frontal cerebral, caudal cerebral,
and cerebellar activity. Cerebellar activity was recorded as a negative control
channel. The final EEG channel was embedded within the dental cement, used to attach
the head-stage, and detected any movement-related or intrinsic noise. Transcranial
electrodes were jewelry screws with a soldered silver wire lead attached to a dedicated
head-stage terminal. All solder was electrically conductive in case of loose attachments.

Figure 8. Electrode Pinout Diagram. Illustration showing the electrode configurations
on the data acquisition plug (Left), with attached amplifier and filter, and EEG head-stage
(Right), showing the receptacle. Permission for publication was obtained directly from
representatives with the manufacturer, Pinnacle Technologies. Image credit: Pinnacle
Technologies, Lawrence, KS.
Surgery
Mice were given a pre-operative subcutaneous dose of buprenorphine sustained
release (SR) analgesic at 0.5 mg/kg at least one-hour prior to anesthesia. Following
buprenorphine acclimation, mice were deeply anesthetized via intraperitoneal injection of
ketamine [12.5 mg/mL]/xylazine [2.0 mg/mL] cocktail. Consciousness was tested by toe
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pinch. Once fully unconscious, mice were mounted in stereotaxic unit with ear and bite
bar. The area of incision was prepared by shaving and sanitization while lubricating gel
(Bausch & Lomb) was applied to the eyes. A midline incision was made to expose the
surface of the skull and any remaining superficial fascia was removed from the surface.
Electrode pilot holes were drilled at the following stereotaxic coordinates (to Bregma, to
Midline): +2.0 mm, ±1.5 mm for EEG #1; -2.75 mm, ±1.5 mm for EEG #2; -7.0 mm,
±1.5 mm for EEG #3; and non-specific placement in dental cement for reference EEG
#4. All Electrode screws were inserted to a depth of approximately 1.0 mm to contact the
cortical or cerebellar surface. All surgeries were performed according to standard
recommendations by the hardware manufacturer, Pinnacle Technologies. Dental cement
was utilized to ensure stable electrode placement and head-stage attachment. Mice were
given an additional dose of buprenorphine SR 72-hours post-surgery. Additionally, mice
were observed for signs of pain, excessive inflammation, and infection daily for at least
one-week post-surgery. Mice were promptly euthanized if they had not eaten in 24hours, showed greater than 20% weight loss, or showed more than three symptoms of
pain and distress (self-mutilation, increased/decreased movement, unkempt appearance,
dehydration, tremor, etc.).
Recording
Mice began treatment phase following 1-week of recovery. For more information
about cirazoline treatment refer to “Animal Use and Treatment” within this
section. Following completion of the treatment phase, mice were allowed to acclimate to
EEG tether for at least 24-hours. An additional 24-hours was allowed for the recording
of baseline observations and comparison between untreated and treated groups. Then,
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mice were injected with kainic acid as outlined above and observed for seizure activity
for 2-hours post-kainic acid injection. Synchronized video or video-EEG data was
collected for later analysis. Video feed was captured by two cameras (Arecont Vision)
opposed at 45-degree angles to maximize probability of optimal viewing angle (Fig. 9).
Video feeds and EEG data were transferred to a custom-built Dell computer workstation
(Pinnacle Technologies) after being passed through a power-over-ethernet switch for
synchronization of feeds. Data was captured internally using Pinnacle Acquisition
software (Pinnacle Technologies) and later transferred to external SATA HDDs (Western
Digital), via hot swap hard drive bay (ThermalTake) for data transfer and archival.

Figure 9. Video and Video-EEG Apparatus. Image generated using Microsoft
PowerPoint 2016. Credit: Pinnacle Technologies, illustration adapted from image on
pinnaclet.com.
Analysis
Data files were blinded as previously described for analysis in Seizure Pro
software (Pinnacle Technologies). Video data was manually scored as previously
outlined. Data was analyzed for manifestation of sub-behavioral threshold seizure
activity. EEG data was assessed for seizures by threshold analysis and line length
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measurement. Additionally, short-time Fourier transformation analysis was utilized to
compare cortical neural oscillatory frequency band intensities between untreated and
treated groups preceding, during, and between seizures. While not implemented here,
basic spatiotemporal mapping was achieved by comparing electrode intensities between
the frontal and caudal cerebral EEG channels.
Statistics
Latency to behaviorally progressive seizures was compared individually by t-test
comparisons. Multiple comparisons were not weighted due to the inevitable and
expected increases variance when measuring separate seizure parameters. Additionally,
the sample of each subsequent latency are representative of subsets of the same
population, measured for different characteristics, no attempt was made at inter-stage
comparisons. A probability of insignificance alpha threshold of P<0.05 was set for
rejection of the null hypothesis. All data are graphically presented as mean±SEM, while
alpha levels are presented as follows: 0.05 (*), 0.01 (**), 0.001 (***).
Results
High Doses of Kainic Acid Show a Consistent Trend of Increased Latency to Seizure
Formation and Intensification in Mice Treated with Cirazoline
In our initial efforts to establish a kainic acid-induced seizure model, a 35 mg/kg
dose of the chemoconvulsant was utilized to assess the potential antiepileptic effects of
long-term α1A-AR activation, with cirazoline. We observed a consistent trend of
increased latency to emergence of seizure activity and intensification in cirazoline-treated
mice (Fig. 10). Specifically, latency to the emergence of grades 2-6 for non-treated
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control mice were as follows: [2] 963.0±149.5 seconds (n=8), [3] 1580.3±310.7 seconds
(n=8), [4] 1771.0±301.5 seconds (n=8), [5] 2101.1±409.1 seconds (n=8), and [6]
2928.6±749.7 seconds (n=8). In comparison, the latency to each stage was somewhat
greater in cirazoline-treated mice: [2] 1753.8±515.8 seconds (n=12), [3] 2337.9±482.5
seconds (n=12), [4] 2556.7±491.9 seconds (n=12), [5] 2748.7±496.1 seconds (n=12), and
[6] 3539.0±692.0 seconds (n=12). Multiple t-test comparisons did not reveal any
statistical differences between cirazoline-treated and non-treated control groups at any
seizure stage. However, the consistent trend of lower values for the emergence of every
stage warranted further investigation. Specifically, we hypothesized that the dosage of
kainic acid may have overpowered inhibitory circuitry and a lower dose may reveal
important differences unobserved at 35 mg/kg kainic acid. Further, we seeked to increase
the number of animals used from each sex in order to investigate any differences in
efficacy.

50

Figure 10. Effect of Cirazoline Treatment on Latency to Emergence and
Progression of Seizures in Response to High Dose Kainic Acid. Mice were
administered intraperitoneal injections of 35 mg/kg kainic acid following an acclimation
period of at least one-half hour. Grades on X-axis are indicative of the presence of the
following behavioral seizure characteristics: (2) prolonged and exaggerated hunched
posture with head bobbing, (3) emergence of pronounced forelimb clonus, (4) emergence
of forelimb clonus and rearing, (5) progression to rearing and falling, (6) loss of postural
control with full body involvement tonic-clonic activity. Being that each measured stage
was from largely the same sample population, and not all mice achieved higher than
grade 2 seizures, we did not account for multiple comparisons in our T-test comparisons.
No statistical significance was observed.
Cirazoline-treated Mice Exhibit Increased Latency to Initial Emergence of Lowdose Kainic Acid-induced Seizures
Next, we assessed the effect of cirazoline treatment on the latency to emergence
and progression of chemoconvulsant-induced seizures by utilizing a lower, 25 mg/kg,
dose of kainic acid. As illustrated in Figure 11, latency to the emergence of grades 2-6
for non-treated control mice were as follows: [2] 816.3±92.6 seconds (n=24), [3]
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3104.5±408.7 seconds (n=24), [4] 4020.8±505.8 seconds (n=24), [5] 5157.5±533.9
seconds (n=24), and [6] 5656.4±495.7 seconds (n=24). In comparison, the latency to
initial stage emergence was somewhat greater in cirazoline-treated mice: [2]
1616.3±382.2 seconds (n=23), [3] 3188.9±523.8 seconds (n=23), [4] 3583.4±524.5
seconds (n=23), [5] 4447.5±608.1 seconds (n=23), and [6] 4914.4±572.8 seconds (n=23).
Because each category represented a separate measurement of the same samples, with
drastically different expected variances, we utilized multiple t-test comparisons, without
correcting for multiple comparisons. This analysis showed a significant difference in the
emergence of grade 2 seizure activity (P=0.04) when comparing non-treated controls and
cirazoline-treated groups. The latency for grade 2 activity was 799.9±385.8 seconds
greater in cirazoline-treated mice, or 198.0±51.9% of control latency.

Figure 11. Effect of Cirazoline Treatment on Latency to Emergence and
Progression of Seizures in Response to Low Dose Kainic Acid. Mice were
administered intraperitoneal injections of 25 mg/kg kainic acid following an acclimation
period of at least one-half hour. Grades on X-axis are indicative of the presence of the
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following behavioral seizure characteristics: (2) prolonged and exaggerated hunched
posture with head bobbing, (3) emergence of pronounced forelimb clonus, (4) emergence
of forelimb clonus and rearing, (5) progression to rearing and falling, (6) loss of postural
control with full body involvement tonic-clonic activity. Being that each measured stage
was from largely the same sample population, and not all mice achieved higher than
grade 2 seizures, we did not account for multiple comparisons in our T-test comparisons.
No statistical significance was observed. Statistical significance is presented, as follows:
P < 0.05 (*), P < 0.01 (**), P < 0.001 (***).
There were no apparent differences between untreated controls and cirazolinetreated groups between males and females (Fig. 12). However, it was apparent that
female mice were apparently more vulnerable to the kainic acid insult than were male
mice, regardless of treatment. While this is an interesting finding, it was not a primary
goal of this study, and so no statistical assessment was performed on this data.

Figure 12. Effect of Cirazoline Treatment on Latency to Emergence and
Progression of Seizures in Response to Low Dose Kainic Acid, Separated by Sex.
Mice were administered intraperitoneal injections of 25 mg/kg kainic acid following an
acclimation period of at least one-half hour. Grades on X-axis are indicative of the
presence of the following behavioral seizure characteristics: (2) prolonged and
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exaggerated hunched posture with head bobbing, (3) emergence of pronounced forelimb
clonus, (4) emergence of forelimb clonus and rearing, (5) progression to rearing and
falling, (6) loss of postural control with full body involvement tonic-clonic activity. No
statistical assessments were performed.
Video-electroencephalography Characteristics of Seizure Activity in Non-Treated
Control and Cirazoline-Treated Mice
Analysis of the previously discussed methods with electroencephalography
confirmed the electrographic nature of the seizures we were characterizing using the
method of Racine. Additionally, we were able to confirm the existence of prominent
EEG seizure activity corresponding with behavioral manifestation, i.e. Racine’s scoring
(Fig. 13).
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Figure 13. Example Video-EEG of Confirmed Seizure Following Intraperitoneal
Kainic Acid Injection. In the EEG trace there is a clear apparent increase in EEG
electrical potential amplitude (mV) and corresponding video indicates Racine’s Grade 2
motor seizure. (A) Still frames from synchronized video recording of seizure, from both
camera perspectives, showing hunched posture, forelimb tonus, nuchal clonus (head
bobbing, not apparent in still), and tail rigidity. (B) EEG trace activity excessive and
hypersynchronized EEG electrical potential (mV) (i.e. a seizure) measured from multiple
electrodes. [1] Trace of left parietal area electrode (to Bregma, to Midline): -2.75 mm, 1.5 mm; [2] Trace of right parietal area electrode (to Bregma, to Midline): -2.75 mm,
+1.5 mm; [3] Trace of combined left-right frontal electrodes (to Bregma, to Midline):
+2.0 mm, ±1.5 mm; (not shown) Trace of acrylic-embedded electrode to capture noise
and movement artifacts. Labelled indicator shows the time point shown in (A).
As summarized in Figure 15, we observed a mean latency to the first EEGconfirmed seizure of 813.5±188.4 seconds (n=4) in untreated control mice and a mean
latency of 912.5±44.2 seconds (n=3) in mice treated with 40 µM cirazoline. These
results seem to suggest a very similar onset latency for initial seizure activity with a slight
delay observed in cirazoline-treated mice; however, a confounding variable is that only
3/5 cirazoline-treated mice exhibited any level of seizure activity. In all kainic acid
studies, we attempted to control for variance in the kainic acid solutions from day-to-day
by performing experiments with both groups, alternating which treatment group
underwent early versus later injections.
Despite attempts to control for any differences in kainic acid doses have noticed
in each set of experiments (35 mg/kg kainic acid, 25 mg/kg kainic acid, and 25 mg/kg
kainic acid with EEG) that there were several mice which did not exhibit any seizure
activity. Specifically, across all kainic acid experiments, 36/36 control mice exhibited at
least low-grade seizure activity, while only 35/40 cirazoline-treated mice exhibited at
least low-grade seizure activity. This phenomenon is interesting considering the findings
of Pizzanelli et al. (2009), which found this to be a very common occurrence in α1B-AR
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knockout mice. However, it is difficult to rule out the possibility of a missed injection, so
we have chosen to present this data without making definitive conclusions.

Figure 14. Latency to Initial Kainic Acid-Induced Electrographic Seizure in
Untreated Control and Cirazoline-Treated Mice. Latency values are presented
separately due to relatively low sample size and high variance. Similarly colored bars are
not corresponded in any way. Each electrographic seizure was identified in Pinnacle
Seizure Pro software by threshold analysis and confirmed with line length analysis, being
defined as at least 2 times greater than background for ≥10 seconds. Noise and
movement artifacts were controlled via a dedicated acrylic-embedded electrode.
Given our previous observations that cirazoline treatment delays the initial onset
of behaviorally-manifested motor seizures, we hoped to characterize the nature of this
sub-behavioral seizure activity in non-treated and cirazoline treated mice (Fig. 15).
Unfortunately, we were unable to collect sufficient data due to the difficult nature of the
electrode implantation surgeries. Interestingly, we noticed a nearly instantaneous spike
in EEG activity following kainic-acid injection. While the high doses of kainic acid were
useful for separating seizure initiation and progression in the treatment groups from a
behavioral perspective, it indicates that we may need to significantly lower the dose of
kainic acid used when assessing sub-behavioral seizure activity.
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Figure 15. Example Video-EEG of Initial Activity Following Intraperitoneal Kainic
Acid Injection. In the EEG trace there is a clear apparent increase in EEG electrical
potential amplitude (mV), but corresponding video shows does not indicate generalized
cognitive impairment. (A) Still frames from synchronized video recordings of possible
mouse seizure activity; [1-4] correspond to the indicators at the bottom of B4. (B) EEG
trace activity showing increased EEG electrical potential (mV) measured from multiple
electrodes. [1] Trace of left parietal area electrode (to Bregma, to Midline): -2.75 mm, 1.5 mm; [2] Trace of right parietal area electrode (to Bregma, to Midline): -2.75 mm,
+1.5 mm; [3] Trace of combined left-right frontal electrodes (to Bregma, to Midline):
+2.0 mm, ±1.5 mm; [4] Trace of acrylic-embedded electrode to capture noise and
movement artifacts.
Spontaneous Epileptic Seizures in α1A-AR Knockout Mice, As Assessed by
Behavioral-Scoring and Electroencephalography
Previous work led by a former Doze lab member, Dr. Katie Collette, observed a
high incidence of seizures in α1A-AR knockout mice. In these observations, 55.8%
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(19/34) α1A-AR knockout mice exhibited seizure activity after handling and during 15minute observations in an open field apparatus. It was noted that all seizures observed
were Racine’s grade 1 or 2. This high incidence was in comparison to wild-type controls
and α1B-AR knockout mice, where no seizures were observed. Interestingly, there was
anecdotal evidence of these seizures for years. During normal cage changes, both
members of our laboratory and members of the CBR staff frequently noted seizures in
these mice. From these anecdotal observations and seizure incidence measurements, we
became interested about the nature of these seizures.
We utilized custom video recording apparatuses to capture behavior of α1A-AR
knockout mice; each recording was for a period of 48-hours. Additionally, we attempted
to minimize stressful stimuli, via the following steps: (1) Each mouse was individually
caged in an observational cylindrical cage lined with normal home cage bedding; (2)
mice received ad libitum access to food and water; (3) a white noise machine was utilized
to decrease extraneous jarring sounds in the environment; (4) Room lights were
automatically timed to mimic home cage light-dark cycles (07:00 on/19:00 off); (5) mice
were allowed to acclimate to observation cages for at least 24-hours before observations
began. We observed 8 α1A-AR knockout mice (4 females, 4 males) for both seizure
incidence and severity, while noting information about time-of-day and activity level
prior to seizure occurrence.
All mice exhibited unusual activity that could have been interpreted as a motor
seizure (e.g. prolonged freezing), but only progressive and obvious seizures were counted
towards analyses. Our observations revealed a confirmed motor seizure incidence of
75% (6/8) during 48-hour of observation. The number and severity of observed seizures
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ranged widely. A total of 26 motor seizures were observed, with a mean prevalence of
3.25±1.65 (Range: 0-14) seizures per mouse. The mean Racine’s grade of observed
seizures was 3.12±0.30, Range: 2-6 (Fig. 16).

Figure 16. Mean Number of Seizures Observed per Mouse, with Mean Seizure
Severity, in α1A-AR Knockout Mice. The mean number of seizures included all mice,
including those which did not exhibit any motor seizure activity. The mean Racine’s
Score was estimated from the aggregated score of all seizures and was not weighted.
Information about seizures in individual mice can be found in Table 1. All values are
represented as mean±SEM.
The majority of seizures were exhibited by one individual, with14 confirmed
motor seizures over the 48-hour recording period. However, the maximum grade
assigned to these seizures was a 3-out-of-6. Two other individuals exhibited several high
grade seizures (grades 4-6), which involve intense tonus and/or clonus, usually involving
the entire body. Finally, the two remaining mice exhibited only one, low-grade motor
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seizure each. A description of individual seizure characteristics, as well as information
about activity level preceding seizure, time-of-day, and sex and age are listed in Table 1.
While seizure start and end times were noted, we did not estimate seizure duration
because of the difficult making an assessment of when a seizure ends without EEG
confirmation. Following the main seizure, there is typically a period of ictal tonic
immobility or normal EEG period with no movement, which are difficult to discern.

60

61

Table 1. Long-term Motor Seizures Recordings in α1A-AR Knockout Mice. Notes of
individual, unprovoked motor seizures in α1A-AR knockout mice. Information about sex,
age, and the nature of each seizure is listed. Seizure characteristics include motor seizure
initiation time, estimated time of cessation, activity level, time of day, and Racine’s
Grade for severity.
In order to assess the validity of our motor seizure assessments, two α1A-AR
knockout mice were fitted with EEG head-stages which measured brain electrical activity
at two leads placed on the left and right hemispheres over the cerebrum. One α1A-AR
knockout exhibited spontaneous seizures over several days of recording, including a
Racine’s grade 5 seizure event (Fig. 17).
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Figure 17. Example of Unprovoked Racine’s Grade 5 Seizure, with EEG, in α1A-AR
Knockout Mouse. (A) Description of seizure phases, including initation, progression,
and cessation. (B) Enlarged image of camera view of Racine’s Grade 5 seizure activity;
shows mouse in unaturally reared posture due to hindlimb tonus prior to exhibiting
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multiple falls. (C) Time-course power spectrum analysis via Short-time Fourier
Tansformation; shows the increase in prevalency of EEG activity throughout all
frequency bands, but especially in low frequencies (<10 Hz; green, yellow, and red on
heat map). (D) EEG trace showing relative amplitude of electrical potential (mV) as
measured from an electrode (other not shown for simplicity). Numbered indicators
correspond with seizure phases described in (A).
Discussion
These experiments represented a new foray for our laboratory into understanding
the role of α1A-AR activity in in vivo models of epilepsy; an essential step to
understanding the translational potential of this receptor. Cumulatively, these
experiments have shown a propensity for α1A-AR activation to increase the latency to
initial seizure onset after kainic acid chemoconvulsant insult, as well as the necessity for
in-tact α1A-AR signaling for maintenance of normal seizure threshold.
Interestingly, the effect size for the latency to initial seizure onset was similar to
that seen in dose-response experiments in hippocampal slices. Unfortunately, the current
experiments would not allow for the resolution necessary to attribute hippocampal α1AAR contributions to the observed difference. However, Pinnacle Technologies has
recently begun offering custom-fitted head-stages with depth electrodes, which are
capable of simultaneously measuring cortical and deep brain EEG. Ultimately, these
results suggest a broader role for α1A-AR activation in the resolution of abnormal brain
activity and seizures. However, more EEG experiments and refinement of surgical
procedures is necessary before definitive statements can be made.
Results in α1A-AR knockout mice revealed interesting findings surrounding the
nature of seizures in these mice. First, we observed that α1A-AR knockout mice indeed
exhibit significant seizure activity devoid of obvious provocation. This suggests that the
seizures observed are spontaneous, but may be worsened with aversive stimuli.
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Additionally, we found that half of the mice observed exhibited multiple seizures over a
48-hour period. Interestingly, this rate of seizure occurrence is similar to guidelines for
epilepsy diagnosis. This may suggest α1A-AR knockout mice as an animal model of
spontaneous epilepsy. Likewise, constitutively active mutant α1B-AR mice have been
described to develop a Parkinsonian phenotype in aged mice and have been documented
to exhibit seizures (Zuscik et al., 2000). Finally, we report that some mice exhibited
Racine’s grade 4-6 seizures (Convulsive, 3-6). This is evidence for potential severe
epilepsy phenotypes in some α1A-AR knockout mice. Our findings, that of the
constitutively active mutant α1B-AR mouse, and previously mentioned findings by
Pizzanelli (2009) suggest a role for the α1-ARs in seizures and epilepsy and a potential of
opposing roles of the α1A-AR and α1B-AR.
Taken together, our results in this study show a clear importance for α1A-AR
function in maintaining normal brain excitability and preventing abhorrent seizure
activity. These data fit well with our findings in hippocampal slices and support our
hypothesis which suggests antiepileptic characteristics of the α1A-AR. However, these
results, in slice and in vivo, suggest a modest or moderate effect elicited from α1A-AR
activation. However, the most significant findings revolve around seizure activity
prevention. Interestingly, previous studies which ablated NE signaling also found the
greatest efficacy in delaying seizure or epilepsy onset, rather than acute differences on
seizure cessation (Giorgi et al., 2004). Future research may find interesting results when
assessing the efficacy of α1A-AR activation in chronic, rather than acute, models of
epilepsy.
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CHAPTER IV
ENDOGENOUS PROMOTER-DRIVEN REPORTER EXPRESSION SUGGESTS
THAT α1A-AR IS OCCASIONALLY CO-LOCALIZED WITH PARVALBUMIN,
BUT IS ALSO MODERATELY EXPRESSED ELSEWHERE IN THE MOUSE
HIPPOCAMPUS
Introduction
Electrophysiological studies in the rat hippocampus and our work, in the mouse
hippocampus, both indirectly suggest that the α1A-AR modulates hippocampal alterations
via actions in inhibitory interneurons (Bergles et al., 1996; Hillman et al., 2007; Hillman
et al., 2009). However, substantiating this hypothesis has proven difficult because of the
lack of any commercially-available antibodies which reliably target the α1A-AR (Jensen
et al., 2009). Thus, in order to circumvent this issue several transgenic mouse models
have been generated which produce reporter proteins, either tagged to the α1A-AR gene
or under the α1A-AR promoter, that can be reliably labelled with immunohistochemical
or immunofluorescence assays. Evidence from reporter imaging and single-cell gene
expression studies have supported this hypothesis and further suggested that the α1A-AR
was expressed on parvalbumin- and somatostatin-expressing interneurons, both common
interneuron subtypes, with implications in epilepsy.
Hillman & colleagues first suggested prevalent α1A-AR co-expression with
somatostatin using single-cell real-time polymerase chain reaction (RT-PCR) (Hillman
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et al., 2005). Subsequent fluorescence imaging of green fluorescence protein (GFP)labelled α1A-AR transgenic mice supported these findings, observing GFP co-localization
on interneurons, identified by markers for glutamic acid decarboxylase (Papay et al.,
2006). Further investigation suggested GFP co-localization with both somatostatin and
parvalbumin (Knudson, 2007). While supportive of the earlier RT-PCR findings, both
the Papay and Knudson experiments identified GFP labelling on hippocampal pyramidal
neurons. These results produced questions because our laboratory was unable to illicit an
α1A-AR response on any pyramidal cells. Ultimately, these results were attributed to the
purposeful overexpression of GFP-labelled α1A-AR. Thus, with the limited scope of
single-cell PCR and the questions surrounding the likely false-positive expression of the
α1A-AR on hippocampal pyramidal neurons, in the GFP-tagged α1A-AR transgenic
mouse, we aimed to investigate α1A-AR reporter expression in a non-overexpressed
model system.
We utilized the α1A-AR knockout mouse, developed by Simson & colleagues, to
investigate α1A-AR reporter immunofluorescence labelling and co-labelling with
parvalbumin-expressing cells in the hippocampus. This knockout mouse has a knock-in
LacZ gene, expressed under the endogenous α1A-AR gene promoter, which allows for
reliable labelling of cells which would normally express the α1A-AR. Further, the
advantage of utilizing LacZ as a reporter is that it allowed for the investigation of
functional characterization of β-Galactosidase enzyme, the protein product of the LacZ
gene, using the X-Gal colorimetric assay.
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Ultimately, the goal of identifying the expression patterns of the α1A-AR in the
hippocampus is aimed at determining the mechanisms by which the α1A-AR alters
interneuron excitability. Current evidence suggests that α1A-AR activation modulates the
excitability of hippocampal interneurons by altering the conductance of outwardlyrectifying potassium channels and hyperpolarization-activated cyclic nucleotide-gated
channels, the so-called “funny current”, and in some circumstances by modulating
sodium channel conductance (Bergles et al., 1996; Hillman et al., 2007). However, these
apparently circumstance-specific mechanisms suggests that there may be several
mechanism by which the α1A-AR modulates effects on brain excitability; therefore it is
important to develop a model to better understand this complex system.
Materials and Methods
Animal Use
Mice were housed in an AALAC-approved facility and all experiments had
IACUC approval. All tissues used in immunofluorescence experiments were prepared
and fixed at the Cleveland Clinic Foundation, under the supervision of Dr. Dianne Perez.
All mice were generated in the Perez laboratory and each mouse is genotyped to ensure
correct mutations.
α1A-AR Knockout Reporter Mouse Generation

α1A-AR knockout reporter mice were generated as previously described (Rokosh
et al., 2002). Briefly, a plasmid vector, containing 1.1 Kb from the 5’ arm and 6.5 Kb
from the 3’ arm, sequence retrieved from the 129/SvJ genomic library, targeted portions
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of critical exon 1 and the adjacent intron for excision from the α1A-AR gene. This vector
also contained a LacZ operon and conferred resistance for neomycin.
The plasmid vector was transfected into RW-4 129/SvJ embryonic stem cells
using electroporation. Positive transfections were identified with neomycin resistance.
Positive cells were cultured and analyzed for correct insertion. A small fraction of
transfected samples contained the correct insertion with no additional random insertions.
These embryonic stem cells were subsequently chosen for insertion into C57BL/6
blastocysts. Blastocysts were implanted into a 129SvJ x FVB/N female; subsequently,
pups were assessed for germ-line expression of the correct mutation.
Finally, heterozygous mutant mice were bred and back-crossed with C57BL/6 and
FVB mice for several generations. These mice are considered congenic to C57BL/6
mice, the stain for which we utilize as “normal” controls (Simpson, 2006).
Tissue Preparation
Adult α1A-AR knockout reporter mice were placed in an empty chamber and
carbon dioxide gas was slowly released, from a compressed gas cylinder, into the
chamber until respiratory arrest was apparent. Mice were quickly transferred out of the
contained where the thoracic cavity was opened and the heart exposed. Mice were then
intracardially perfused with 37oC PBS through the left ventricle, while a small incision
was made to the right atrium. PBS was perfused until the effluent from the right atrium
was completely clear. Following clearance of blood, the perfusion solution was switched
to ice-chilled (2-4oC) 4% paraformaldehyde (Fisher Scientific). Successful fixation was
assessed by rigor of the appendages.
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Next, the head was decapitated and the skull was exposed via an incision down
the midline. The brain was exposed by carefully removing the remainder of the cervical
vertebra, and subsequently, using a scissor to cutting the skull, posterior to anterior,
initiated from the foramen magnum. After careful removal of the skull, a spatula was
used to slowly remove the brain. Isolated brains were post-fixed in 4%
paraformaldehyde (Fisher Scientific) for 4 hours, at 4oC. After 4 hours, brains were
washed in and transferred to fresh PBS. Finally, in preparation for sectioning, brains were
transferred 15% sucrose (Fisher Scientific) in PBS, then twice transferred to fresh 30%
sucrose in PBS, each time equilibrating at 4oC.
Functional β-Galactosidase Visualization
For functional expression experiments, brains fixed according to the previously
outlined parameters and sent to the Bergles laboratory, at the Johns Hopkins University,
where they were sectioned and stained with X-Gal reagent. Briefly, brains were
sectioned in the coronal or sagittal planes, at 35-µm intervals, using a vibrating
microtome (Leica VT1000S). Next, tissue slices underwent β-Galactosidase-X-Gal
enzymatic reaction, according to an optimized protocol (Bergles Laboratory). Finally,
tissue was mounted and visualized using a light microscope.
Sectioning for Immunofluorescence
For immunofluorescence experiments, brains were trimmed and flash frozen with
dry ice-cooled isopentane (Fisher Scientific) in optimal cutting temperature compound
(OCT)(Leica) and transferred to a refrigerated cryostat (Leica) cooled to at least -20oC.
14-µm thick coronal sections were made and individual slices were transferred to room
temperature glass slides (VWR) subbed in gelatin. Slides were evaluated for the presence
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of the hippocampi and transferred to a -80oC freezer (So-Lo) until ready for
immunostaining.
Immunofluorescence Labelling
Slides were removed from the freezer and allowed to desiccate at room
temperature for at least 2-hours prior to proceeding with the immunostaining procedure.
Slides were inserted into a copplin jar with 1xPBS to dissolve OCT and then laid flat and
marked with a pap-pen (Fisher Scientific) to form a hydrophobic barrier.
Tissue was blocked and permeabilized by applying a sufficient volume of
Incubation Solution, consisting of Block-Aid Blocking Solution (ThermoFisher) and
0.1% Triton X-100 Surfact-Amps Detergent Solution (ThermoFisher), over the sample to
completely immerse the sample. Tissue samples were incubated in this solution, at room
temperature, for 1-hour. A subset of samples underwent an antigen retrieval procedure
prior to blocking. This procedure consisted of the following steps: A 1-hour incubation
in zinc-formalin (10%) buffer (ThermoFisher), at room temperature; followed by
thorough rinsing and an incubation in 1:100 citrate buffer (Vector Labs), pH 6, at 9095oC, for 10 minutes. Then, samples underwent the normal blocking and
permeablization procedure outlined above.
Following blocking and permeablization, slides were incubated with a primary
antibody mixture, Rabbit anti-β-Galactosidase (mouse epitope) 1o Polyclonal Antibody
[Novus, NB600-305] and Goat anti-Parvalbumin (rat epitope) 1o Antibody [Swant,
PVG213], diluted in incubation solution. Slides were coverslipped and incubated
overnight, in a moistened box, at 4oC. After overnight incubation with primary
antibodies, slides were rinsed at least 3 times with 1xPBS for 5-minutes. Then, slides
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were incubated with secondary antibodies, Donkey anti-Rabbit IgG (H+L) Highly CrossAdsorbed 2o Antibody, Alexa Fluor 568 (ThermoFisher, A-10042) and/or Donkey antiGoat IgG (H+L) Cross-Adsorbed 2o Antibody, Alexa Fluor 488 (ThermoFisher, A11055), mixed or separately, for 1-hour, at room temperature, in a foil-covered box.
Following secondary antibody incubation, slides were again rinsed at least 3 times, for 5minutes, in 1xPBS. Finally, slides were mounted with 2-3 drops per slice of ProLong
Gold Antifade Moutant with DAPI (ThermoFisher) and a #1 glass coverslip was carefully
applied to avoid trapping of air bubbles. Coverslip mountant was allowed to cure for at
least 24- to 48-hours, in darkness, prior to proceeding to imaging.
Imaging
Slides were carefully cleaned and placed onto the stage of a Leica TCS SPE DM5500
Scanning Confocal Microscope for imaging. Slides were imaged with laser lines at 405
nm, 488 nm, and 594 nm and corresponding emission filters. Slides were imaged with
10x, 20x, 40x, or 63x objectives, with a 1.5x digital zoom. The 20x, 40x, and 63x
objectives were oil-immersion objectives. Images were captured using Leica LAS X
imaging software.
Analysis
Images were analyzed using Leica LAS X image analysis software. No statistical
analyses were performed in these experiments since the outlined goal of the study was to
perform a qualitative assessment.
Results
Functional α1A-AR Reporter Distribution in the Mouse Brain
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Our initial efforts in assessing α1A-AR distribution within the mouse brain
entailed utilizing the α1A-AR knockout mouse line, which expresses a LacZ operon under
the endogenous α1A-AR gene promoter to produce β-Galactosidase protein. We
investigated the broad brain expression patterns and fuctionality of the β-Galactosidase
reporter protein using X-Gal staining, a synthetic galactose substitute, which undergoes a
colorimetric shift when cleaved by β-Galactosidase. The product of this reaction stains
the puncta containing this protein a dark blue hue and is indicative of the presence of
functional protein expression, under the endogenous gene promoter. As shown in in
Figure 18, there was broad expression of fucntional β-Galactosidase throughout the brain,
with localized areas of high density expression. Particularly, we noted dense expression
within the deep layers (layers 4/5) of the cortex and moderate expression within the
hippocampus.
While expression patterns within the cortex were interesting and unexpected, little
is known about the function of the α1A-AR on the cells within this area, so our analysis
going forward focused on the expression within the hippocampus. Broadly speaking, we
observed stained puncta distributed fairly evenly throughout the hippocampal regions and
layers. The density of stained puncta was somewhat greater within the dentate gyrus and
were prevalent in the stratum lacunosum-moleculare, a layer of less cell density. Next,
we sought to investigate the laminar and regional distribution of puncta using
immunofluorescence labeling because this technique allows more specificity when
estimating laminar margins and allowed us to investigate the hypothesis that the α1A-AR
is predominantly expressed on parvalbumin-positive cells; this is a group of cells,
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expressed in the hippocampus and elsewhere in the brain, previously shown to be almost
exclusively indicative of a sub-population of inhibitory interneurons

A

B
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Figure 18. X-Gal Staining of Puncta Expressing Functional α1A-AR Reporter, βGalactosidase. Low (4x) magnification of the brain, showing the hippocampus, in (A)
parasagittal plane (B) coronal plane.
Evaluation of Hippocampal Laminar and Regional Distribution of DAPI-Stained
Cell Nuclei Using Confocal Fluorescence Microscopy in Mouse Brain
Laminar distribution of cells-of-interest were characterized based on relative
position to the tightly organized and densely packed pyramidal layer of Ammon’s Horn
(cornu ammonus) and granule layer of the dentate gyrus (fascia dentata), within the
hippocampus. These layers are readily apparent in fluorescence imaging with DAPI
nuclear stain. Margins of other hippocampal layers were generally estimated based upon
regions of intermediate or sparsely dense nuclear-stained puncta superficial and deep to
the readily apparent pyramidal and granule layers. Further, we estimated the regional
distribution of the cells of interest. Generally, in addition to the identifying positioning
within the dentate gyrus (DG) or Ammon’s Horn (CA), it is important to differentiate
between regions of Ammon’s Horn due to discrete fiber innervation patterns in this
reticulated structure. These laminar separations and regions can be visualized in Figure
20, which is a low (20 by 1.5x) magnification stitching of several imaging fields from the
same hippocampal slice. This magnification was utilized, rather than a lower
magnification, because it allows high enough resolution to see individual punctum.
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Figure 19. Panoramic Stitch of DAPI-stained Puncta Throughout the Mouse
Hippocampus. Several low (20-by-1.5x) magnifications imaging fields were stitched
together to form an overview of puncta organization throughout the entirety of the mouse
hippocampus. These particular images are from negative 2o only control slice, showing a
dorsomedial slice of the left hippocampus. All apparent immunofluorescence was
indicative of DAPI. The legend of the figure illustrates the color-coding scheme used to
approximate the various hippocampal regions and strata.
The layers, or strata, we estimated, in order from superficial to deep, were as
follows: (in Ammon’s horn) stratum oriens, stratum pyramidale, stratum radiatum, and
stratum lacunosum-moleculare; (in dentate gyrus) stratum moleculare, stratum
granulosum, and hilus. Additional layers, stratum alveus and stratum lucidum, are
sometimes differentiated, but are region specific and were not readily identifiable the
sections observed, with fluorescence nuclear staining; nor were the strata lacunosum and
moleculare, of Ammon’s Horn easily differentiated, though this is less commonly done in
the literature. Most generally, the value of this laminar assignment is to give the reader
an idea of what type of cell may be expressing the marker-of-interest; although this is
only circumstantial in nature, the existence of excitatory neurons almost solely within the
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densely packed stratum pyramidale and stratum granulosum is well-known and provides
preliminary evidence for future imaging studies and provides insight into observations
made in electrophysiological experiments performed in the hippocampal slice.
The regions we estimated include the DG, CA1, and CA3. The CA2 is a small
region between the CA1 and CA3 which is not easily differentiated using these methods
and is typically not associated with the main signaling pathway of the hippocampus, the
perforant path. In the case of a cell-of-interest being expressed between the estimated
distal margin of the CA1 and the proximal margin of the CA3, where the CA2 likely
exists, this was noted and the puncta were assigned to the closer of the CA1 or CA3. It is
also noteworthy that unlike in humans and other mammals, there is not generally a CA4
region and instead the CA3 is directly adjacent to the hilus of the dentate gyrus. As
previously alluded to, we also estimate sub-regions for the CA1 and CA3, which are
divided as a, b, and c, based on being proximal, middle, or distal to the entorhinal cortex,
for the CA1, or to the CA1, for the CA3.
While this characterization methodology is highly subjective, it allows for a much
more contextual description when the cells are imaged at higher magnification and the
larger, more apparent structures are not observable. Ultimately, it was often necessary to
image at high (63-by-1.5x) magnification because of relatively weak
immunofluorescence signal-to-noise ratios. The provision of the low magnification
stitched image should lend to greater reproducibility and enable other observers to
calibrate their assessments to their own margins.
Antigen Retrieval
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The immunofluorescence staining methods used were generally successful for
identifying cells expressing the α1A-AR reporter and/or parvalbumin. Initially,
fluorescence signal intensity was especially low for the α1A-AR reporter, but we were
confident that we were observing cells that were showing fluorescence. To address this
issue, a protocol for antigen retrieval was implemented. This antigen retrieval was
successful (Fig. 20); however, it did seem to intensify the background signal intensity,
especially apparent with the parvalbumin-indicated puncta. As shown below, the
fluorescence intensity was great enough to make qualitative conclusions about the nature
of α1A-AR reporter expression and its propensity for co-labelling with parvalbuminpositive cells, in the mouse hippocampus.

Figure 20. Effect of Antigen Retrieval on Typical Fluorescence Signal Intensity (a)
High, 63-by-1.5x, magnification image of a punctum with weak β-Gal
immunofluorescence and possible parvalbumin immunofluorescence without antigen
retrieval. This punctum was imaged within the stratum radiatum layer of the CA1a
region of the mouse hippocampus. (b) High, 63-by-1.5x, magnification image of a
punctum exhibiting good β-Gal fluorescence. This image was captured form the stratum
oriens layer of the CA1b region, near the upper blade of the stratum granulosum of
another mouse hippocampus.
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Hippocampal Puncta α1A-AR Reporter Immunofluorescence
Immunofluorescence imaging of the α1A-AR reporter, β-Gal, suggested a low-tomoderate rate of expression, which was consistent with the hippocampal expression of
the same reporter exhibited in X-Gal functional protein colorimetric staining. As seen in
Figure 21, β-Gal was not exclusively colocalized with parvalbumin-positive puncta.
While this finding partially refuted our hypothesis about α1A-AR expression on
hippocampal interneurons, it also provided an opportunity for additional qualitative
comparisons of expression patterns on this elusive receptor. Specifically, we observed
that relative to parvalbumin-positive puncta, there were far fewer (less than half) puncta
positive for β-Gal. Further, although there were instances where β-Gal and parvalbumin
fluorescence did colocalize, it was on the minority of β-Gal positive puncta, estimated to
be about one-fourth to one-third of total puncta observed. However, it is worth noting
that because of our utilization of coronal brain slices, the CA3 region of the hippocampus
tended to be less developed and organized, than can be observed in the middle and
ventrolateral portions; therefore, it remains possible that our sampling could be underrepresentative of the expression of the α1A-AR reporter. However, we did find several
examples of β-Gal positive puncta in the CA3 region, so we did not section along other
axes.
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Figure 21. Example Image Showing Non-exclusive β-Gal-Positive and
Parvalbumin-Positive Puncta in the Mouse Hippocampus. High, 63-by-1.5x,
magnification image of a β-Gal-positive punctum (red) and a parvalbumin-positive
punctum (green) near the stratum granulosum of the dentate gyrus.
In comparison to parvalbumin-positive puncta, we estimated the β-Gal positive
puncta to be more uniformly distributed throughout the hippocampus. We found
examples of β-Gal positive puncta present within every region of the hippocampus and
the expression within the stratum lacunosum-moleculare seemed especially noteworthy
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(Fig. 22). While parvalbumin-positive puncta were most dense in the stratum oriens, βGal positive puncta were found about as often in the stratum oriens and stratum
lacunosum-moleculare, and did seem to be more prevalent than β-Gal positive puncta in
the stratum lacunosum-moleculare. Additionally, β-Gal positive puncta were commonly
found in the area of the subgranular zone and hilus of the dentate gyrus (Fig. 22F).
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Figure 22. Examples of β-Gal Positive Puncta Throughout the Hippocampus. (A)
High, 63-by-1.5x, magnification image of a β-Gal positive punctum in the area of the
subgranular zone of the stratum granulosum of the dentate gyrus. (B) High, 63-by-1.5x,
magnification image of a β-Gal positive punctum in the hilus of the dentate gyrus. (C)
High, 63-by-1.5x, magnification image of a β-Gal positive punctum in the stratum oriens
of the CA3a subregion of the hippocampus. (D) High, 63-by-1.5x, magnification image
of a β-Gal positive punctum in the stratum oriens of the CA1a subregion. (E) High, 20by-1.5x, magnification image of a β-Gal positive punctum in the stratum oriens of the
CA1b subregion. (F) Low, 20-by-1.5x, magnification image of several β-Gal positive
puncta within the upper hilar layer of the dentate gyrus, the stratum radiatum of the
CA3c subregion, and the stratum lacunosum-moleculare of the CA1b subregion.
Hippocampal Puncta Parvalbumin Immunofluorescence
Throughout the hippocampus, many puncta exhibited fluorescence indicating the
presence of only parvalbumin. Figure 23 shows two such examples. The localization of
these puncta were consistent with interneurons. On the occasion that a punctum was
found in the excitatory cell layers, it was alone and adjacent cells were not exhibiting
fluorescence as would be the expectation if observing expression in pyramidal
(excitatory) cells. We estimated higher occurrence of parvalbumin-expressing puncta in
the stratum oriens than in other hippocampal layers.
A

B
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Figure 23. Example Images of Showing Parvalbumin-Positive Puncta in the Mouse
Hippocampus. (A) High, 63-by-1.5x, magnification image of a parvalbumin-positive
punctum near the stratum radiatum of the CA3c subregion. (B) High, 63-by-1.5x,
magnification image of a parvalbumin-positive punctum near in the hilus of the dentate
gyrus.
Hippocampal Puncta Co-labelled for α1A-AR Reporter and Parvalbumin
Immunofluorescence
Co-localization of the α1A-AR reporter, β-Galactosidase, and parvalbumin was
determined by qualitative assessment of relative fluorescence intensity, compared with
the adjacent background in each channel, corresponding to the fluorescence emission
band for each secondary antibody, and the overlap on a DAPI-positive punctum (Fig. 24).
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Figure 24. Separated Fluorescence Emission Channels and Combined Overlay. Low
(20-by-1.5x) magnification images showing the fluorescence in individual emission
channels of a punctum within the stratum oriens of the CA1c sub-region of the mouse
hippocampus (also shown at high magnification in Figure 25C). (A) Pseudo-colored
representative image of fluorescence emission intensity elicited by laser excitation and
corresponding emission filters at 594 nm. This channel corresponds to fluorescence
signal from a primary antibody specific to the α1A-AR reporter, β-Galactosidase, and an
Alexa Fluor 568 fluorophore-conjugated secondary antibody (B) Pseudo-colored
representative image of fluorescence emission intensity elicited by laser excitation and
corresponding emission filters at 488 nm. This channel corresponds to fluorescence
signal from a primary antibody specific to parvalbumin, and an Alexa Fluor 488
fluorophore-conjugated secondary antibody. (C) Pseudo-colored representative image of
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fluorescence emission intensity elicited by laser excitation and corresponding emission
filters at 405 nm. This channel corresponds to fluorescence signal from DAPI. (D)
Pseudo-colored representative overlay image of all fluorescence emission channels
combined.
We observed co-localization on puncta almost exclusively within the regions of
Ammon’s Horn (CA1-3), with very few puncta apparent within the dentate gyrus.
Additionally, the majority of co-labelled puncta seemingly were localized within the
stratum oriens layer of Ammon’s Horn. This may be partially due to the overall low
apparent density of parvalbumin-positive puncta within the dentate gyrus and the
apparent higher density of these puncta within the stratum oriens. That said, we did
observe occasional overlap within the stratum lacunosum-moleculare (Fig. 25D). Figure
25 shows representative images of several co-labelled puncta indicating the presence of
both the α1A-AR reporter, β-Galactosidase, and parvalbumin. The fluorescence intensity
from the 488 nm channel (green), parvalbumin, was typically greater than was observed
in the 594 nm channel (red), β-Galactosidase. Thus, in overlay images the green tends to
be the dominant feature. As mentioned, the likelihood of positive co-localization was
determined by the puncta-to-background, fluorescence emission intensity and the
presence of DAPI-positive nuclear material; the degree to which puncta were more or
less dominated by either marker was not assessed.
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Figure 25. Puncta Showing Co-localization for β-Gal and Parvalbumin in
Throughout the Mouse Hippocampus. β-Gal is shown as red and Parvalbumin is
shown as green. (A) High (63-by-1.5x) magnification image of a co-labelled cell
punctum in the CA1c stratum oriens. (B) High (63-by-1.5x) magnification image of a colabelled cell punctum in the CA1b stratum oriens. (C) High (63-by-1.5x) magnification
image of a co-labelled cell punctum in the CA1c stratum oriens. (D) High (63-by-1.5x)
magnification image of a co-labelled cell punctum in the CA3b stratum lacunosummoleculare. (E) Low (20-by-1.5x) magnification image of a co-labelled cell punctum in
the CA3a stratum oriens. (F) Low (20-by-1.5x) magnification image of a co-labelled cell
punctum in the CA1c stratum oriens.
Other Observations of Immunofluorescence Outside of the Immediate Purview of
this Study
A separate interest of our lab is the potential role of the α1A-AR in adult
neurogenesis. Consistent with previous findings, we did find many examples of α1A-AR
reporter-positive puncta within the apparent margins of the subgranular zone of the
dentate gyrus (Fig. 26). The subgranular zone of the hippocampus, along with the
subventricular zone of the rostral migratory stream, are two known areas within the adult
brain which maintain active pools of neuronal and glial progenitor cells. Unfortunately,
the methodology used in this study did not allow for the assessment of these puncta for
the characteristics of hippocampal progenitor cells. However, the prevalence of α1A-AR
reporter-positive puncta in this neurogenic area at least lends credence to our hypothesis
for future investigations.
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Figure 26. Potential Hippocampal Progenitor Cells Expressing the α1A-AR
Reporter. Low (20-by-1.5x) magnification image of α1A-AR reporter-positive puncta
within the apparent margins of the subgranular zone of the dentate gyrus of an adult
mouse hippocampus.
Negative Controls
To assess antibody cross-reactivity and the possibility of emission spectra
overlap, we utilized individual negative no secondary controls, for each antibody, as well
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as a double-negative no secondary antibody control with each set of immunofluorescence
staining. Following our implementation of antigen retrieval, we were confident that each
antibody was labeling specifically, well above background fluorescence intensity.
In no β-Gal secondary antibody control samples, we observed strong staining on
puncta throughout all samples (Fig. 27A). Additionally, even at lower magnifications,
where higher laser power was required to produce similar puncta intensity, producing
some background fluorescence, there was very little, if any, β-Gal excitation channel
bleed-though from the parvalbumin secondary antibody emission (Fig. 27B). We did
attempt to visualize any bleed-through from the β-Gal excitation channel by tuning the
laser to a very high intensity, but only a very low background fluorescence became
apparent (Figure not shown). None of this background fluorescence was denser on any
puncta.
A

B

Figure 27. No β-Gal Secondary Antibody Control Samples. (a) High, 63-by-1.5x,
magnification image of a no β-Gal secondary control sample with a cell exhibiting
fluorescence for parvalbumin, within the stratum radiatum layer of the CA1a region of
the mouse hippocampus. (b) A low, 20-by-1.5x, magnification image of a no β-Gal
secondary control sample showing several cells with fluorescence indicating the presence
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of parvalbumin, within the stratum oriens layer of the CA1b region of another mouse
hippocampus.
Next, we performed the same assessment with a no parvalbumin secondary
antibody control. There results were similar to those in the no β-Gal secondary antibody
control samples. We did not observe any emission bleed-through from the parvalbumin
excitation channel at the laser powers utilized to image puncta, at high or low
magnification (Fig. 28). Even at higher laser powers, we observed only very slight
fluorescence from the parvalbumin emission channel, which was uniformly distributed
equally and did not skew the pseudo-coloration of the β-Gal positive puncta in channel
overlaps.
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Figure 28. No Parvalbumin Secondary Antibody Control Samples. (a) High, 63-by1.5x, magnification image of a no parvalbumin secondary control sample with a cell
exhibiting fluorescence for β-Gal (red), within the stratum lacunosum-moleculare layer
of the CA1a region of the mouse hippocampus. (b) A low, 20-by-1.5x, magnification
image of a no parvalbumin secondary control sample showing a cell with fluorescence
indicating the presence of β-Gal (red), within the hilar layer of the dentate gyrus region,
near the lower blade of the stratum granulosum, of another mouse hippocampus.
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Finally, for each experiment, we performed a double-negative control, which did
not contain the secondary antibodies for either primary antibody of interest. We did not
observe staining of any cells in these samples (Fig. 29). Similar to previous attempts to
visualize any non-specific fluorescence, laser powers well above those used to image
cells did not yield fluorescence staining of any puncta (Figure not shown). Generally,
only nuclear staining of cell nuclear material, from DAPI, was observable in these
samples.

A

B

Figure 29. No Secondary Antibody Control Samples. Only DAPI nuclear staining is
visible in these images. (a) High, 63-by-1.5x, magnification image of a no secondary
control sample with no cell puncta exhibiting fluorescence. This image was taken from
within the stratum oriens layer of the CA1b region of the mouse hippocampus. (b) A low,
20-by-1.5x, magnification image of a no secondary control sample no cell puncta
fluorescence. This image was from the interface between the CA3a and CA3b subregions of the same mouse hippocampus.

Discussion
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While the research presented here, and previous research from our laboratory and
others, have provided a great deal of insight into the functional role of the adrenergic
receptors in the hippocampus, the actual location of the receptors has remained somewhat
of a mystery. Largely, this has to do with minor variability of the AR subtypes, which is
especially true of the α1-AR class (Hwa et al., 1995; 1996). In fact there are very few
“selective” ligands that can differentiate α1A-AR and α1B-AR function, and as mentioned
earlier, no known commercially-available antibodies for the α1A-AR (Jensen et al., 2009).
Several approaches have been attempted to circumvent the visualization issue with mixed
success. The laboratory of Dianne Perez attempted to visualize the α1A-AR using an
overexpression vector, containing a green-fluorescent protein tag; upon further
investigation, we could not find any effects of pharmacological stimulation of the α1AAR on many of the cell populations and suggested false-positive expression. Others have
utilized radiometric imaging of radioisotope-tagged ligands to infer general density of the
α1A-AR, in the presence, or absence, of selective antagonists. These methods were very
useful for identifying the receptor density in different brain regions and sub-regions, but
lacked the resolution necessary to visualize individual cells, or even laminar distribution
within a sub-region. Thus, we decided to utilize a technique, in a novel fashion, which
had been used for other studies and provided results consistent with physiology studies.
Our approach to was to visualize the α1A-AR by using the transgenic α1A-AR knockout
mouse that had a LacZ insert, expressed under the control of the endogenous gene
promoter. To our knowledge, this study and our collaborators were the first investigators
to implement fluorescence microscopy with this model to visualize brain tissue.
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Specifically, the goal of this study was to investigate the propensity for co-labelling of
the α1A-AR on puncta exhibiting the interneuron marker, parvalbumin.
Our experiments provided support and/or novel insight to many of our questions.
First, our hypothesis that the α1A-AR is primarily localized to interneurons seems to be
supported by these findings. We observed that the α1A-AR reporter was expressed almost
entirely outside of the hippocampal layers where excitatory cells are found. While our
hypothesis remains that these cells are inhibitory interneurons, we cannot rule out the
possibility that these are excitatory neurons or glial cells. Next, our hypothesis that the
α1A-AR is primarily localized on parvalbumin-expressing cells was partially refuted by
these experiments. Instead, we observed that the majority of α1A-AR reporter-expressing
cells did not co-localize with parvalbumin-positive puncta. This suggests that there are
likely other populations of interneurons expressing the α1A-AR within the hippocampus.
Our collaborators in the Bergles laboratory have taken more interest in the possibility of
α1A-AR expression on glial populations, in the hippocampus and elsewhere. An
alternative hypothesis remains, in that previous experiments in our laboratory found gene
expression evidence suggesting that α1A-AR expression may be prevalent on
somatostatin-expressing interneurons. However, what can be definitively concluded
from these experiments is that, unsurprisingly, the hippocampal α1A-AR expression is not
as simple as was initially hypothesized.
Our experiments, using LacZ-mediated reporter labelling, provides a framework
for investigating the distribution patterns of the α1A-AR so that the mechanism(s) of
action can be more precisely defined. Our specific interest in α1A-AR co-expression on
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parvalbumin-expressing interneurons is based on the demonstrated role of parvalbuminexpressing interneurons in epilepsy. This cell type has been shown to be especially
vulnerable to seizure-induced cell death (Dinocourt et al., 2003). Additionally, these
experiments were done in conjunction with a collaborator, Dwight Bergles, whose
laboratory is developing several cell-type specific, conditional knockout mice; the first of
which is the α1A-AR-Parvalbumin knockout. Our results suggested an α1A-AR laminar
distribution consistent with hippocampal interneurons and showed that some of these
cells did indeed co-label on parvalbumin-expressing cells.
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CHAPTER V
DISCUSSION
This dissertation research has revealed several novel findings about the
contributions of α1-AR subtypes to shifting seizure threshold. This work has built
significantly upon our previous work identifying hippocampal sites of action for the α1AR subtypes and the functional consequences of α1-AR activation on hippocampal
inhibitory tone. Our initial primary challenge was the conversion from studying rats to
using mice. Historically, our laboratory has exclusively utilized rats for
electrophysiological experiments. Although mice and rats are anatomically similar, the
primary challenge with switching to mice revolved around the relatively small scale of
the mouse brain, compared with the rat. This presented unique challenges, especially in
the fine-tuning of our electrophysiological preparation protocols and with the level of
fine-motor skills required to prepare hippocampal slices and surgeries involving EEG
head-stage implementation.
The primary advantage of utilizing mice is the broad availability of genetically
modified mice, including the existence of transgenic constitutively active mutant and
knockout variants of the α1-AR subtypes. Additionally, we have recently begun a
collaboration with the laboratory of Dwight Bergles at the Johns Hopkins University,
which is focused on producing several inducible cell-specific knockout mouse lines for
studying α1A-AR function in discrete brain cell populations. The value in such a
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collaboration is great from both basic science and translational investigation perspectives;
cell-specific knockout will allow for an unprecedented level of specificity of the
physiological mechanism(s) of α1A-AR function in the brain. Unlike traditional
pharmacological approaches, the findings should allow for more comparability between
in vitro and in vivo experiments. Additionally, inducible gene knockout allows for the
delineation of knockout consequences to developmental abnormalities versus inherent
physiological changes to a normally-developed system; this is a major limitation of our
current generation of α1-AR subtype knockouts, especially when attempting to draw
conclusions about our findings pertaining to altered epileptiform frequency and
spontaneous, recurrent seizures in α1A-AR knockout mice.
Our findings herein relied heavily on the implementation of α1-AR subtype
knockout mice, which allowed us to differentiate between α1A-AR and α1B-AR
contributions, in a highly specific manner, for the first time. In addition to our inclusion
of novel methods for assessing AR subtype contribution in models seizure and epilepsy,
our development of in vivo models provides a robust foundation for testing α1A-AR
modulation in a more biomedical-relevant paradigm. The opportunity to implement
state-of-the-art synchronized, long-term video and long-term video-EEG recordings into
my studies was instrumental to the success in developing these in vivo models.
Broadly speaking, our results were significant for showing the antiepileptic
properties of the α1A-AR, both in vitro and in vivo; our characterization of detrimental
effects of α1A-AR knockout, both in vitro and in vivo; as well as our novel approach to
utilizing the α1A-AR knockout as a fluorescence microscopy reporter strain.
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Overall, this dissertation research resulted in some exciting discoveries which progressed
our depth of knowledge about this topic, a confirmation of previous results, and an
evolution to our current hypotheses.
Electrophysiological Findings in Hippocampal Slice
In Chapter 2, we presented results from our work with the hippocampal slices in a
magnesium-deprivation model of epileptiform activity. These experiments resulted in
several exciting findings. The general conclusion from these findings was that α1A-AR
expression and activity was essential for α1-AR-mediated alterations to epileptiform
frequency. Additionally, we found surprising alterations to baseline epileptiform
frequency in α1A-AR knockout mice, which may provide exciting insight into the
physiological mechanisms underlying in vivo observations.
First, we showed that activation of the α1-AR, via pharmacological manipulation,
resulted in similar effects to those seen in rat; these findings were a moderate decrease in
hippocampal epileptiform frequency, upon α1-AR activation. This was important
because it suggests that the same physiological mechanisms may be underlying this
phenomenon and that the effects are consistent across species. Our laboratory has spent a
number of years painstakingly characterizing the effects of AR activation, from the
single-cell level, to local neuronal networks (such as inhibitory post-synaptic current and
excitatory post-synaptic potential alterations), and at the level of the local field potential.
Our experiments focused on experimental measurement of alterations in local field
potential.
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Observations of local field potential allowed for observations of epileptiform
synchronicity and phasic changes to the waveforms and frequencies of the epileptiform
population. The downside to local field potential measurements, as opposed to singlecell recordings, is that there is a loss of fidelity as electrical potentials encounter
constructive and destructive interference. Generally, local field potential measurements
provide a more accurate assessment of the total effect of α1A-AR activation or loss, but
does so at decreased resolution of subpopulation differences and other extraneous factors,
which may mask effect size. However, ultimately, a seizure is a manifestation of
congruent neuronal activity, which makes the local field potential a powerful tool for
studying seizures and epilepsy. The hippocampus is of particular interest because it is a
highly vulnerable brain structure to seizure activity and is point of origin for the most
commonly diagnosed and most commonly medically-intractable focal epilepsy, mesial
temporal lobe epilepsy.
Our findings in the mouse hippocampus, suggested that α1A-AR activation results
in a consistent, moderate decrease in epileptiform burst frequency, resultant from
exposure to both endogenous and synthetic AR agonists. These results were consistent
with findings in the rat and extended this effect to the CA3 field of the hippocampus.
Previous studies had only measured CA1 hippocampal alterations. We found a consistent
efficacy, around 15%, for all ligands. This may not seem impressive without proper
context. In the magnesium-deprivation model of epileptiform generation, the lack of
magnesium abolishes the magnesium block of NMDA glutamate receptors, but does so
nonspecifically. In practice, this means that both excitatory and inhibitory circuits enter a
hyperexcitable state. Our hypothesis suggests that the α1A-AR mediates its actions by a
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hyperexcitation of inhibitory interneurons. Evidence within the magnesium deprivation
model suggests that epileptiform bursts only arise once the more prevalent excitatory
neurons overcome the compensatory actions of the inhibitory neurons. Thus, logic
dictates that the inhibitory neurons are likely already firing near maximum capacity. This
reduction in epileptiform burst frequency strongly suggests increased inhibitory
contributions, which without increased excitatory sensitivity (from abolishment of
magnesium block), may be sufficient to increase seizure resistance/threshold, reduce
seizure prevalence, and/or decrease seizure intensity or duration in epilepsy.
Additionally, we made several novel findings, in this model, with hippocampal
slices from α1A-AR and α1B-AR knockout mice. Using these mice, we were able to
clearly show that the α1A-AR is the prominent α1-AR subtype mediating decreases in
epileptiform frequency. α1A-AR knockout resulted in complete abolishment of
phenylephrine-mediated decreases in epileptiform burst frequency, whereas α1B-AR
knockout did not elicit any measurable changes in epileptiform burst frequency when
compared to the efficacy measured in hippocampal slices from wild-type control mice.
Another surprising finding with these knockout mice arose from measurements of
baseline epileptiform burst frequencies hippocampal slices from wild-type control mice
and in α1-AR subtype knockout mice. While α1B-AR knockout had no measureable
difference from the baseline burst frequencies in the wild-type controls, slices from α1AAR knockouts exhibited baseline epileptiform burst frequencies which were more than
1.5-fold greater than wild-type controls. While the constitutive α1A-AR knockout mouse
strain does not allow us to delineate whether this is a developmental consequence or a
sign that α1A-AR activity is necessary for normal hippocampal physiology, it does clearly
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suggest a difference in excitatory-inhibitory balance in these slices. Further, this finding
provides an interesting contextual clue as to the nature of spontaneous seizures observed
within α1A-AR knockout mice.
Findings in vivo
In Chapter III, we described our findings from experiments performed in vivo.
Particularly, our experiments investigated the effects of α1A-AR activation in a model of
acute status epilepticus, as well as a characterization of seizure prevalence and severity in
α1A-AR knockout mice, over a 48-hour observation period. To our knowledge, this was
one of the first investigations into α1A-AR effects in vivo. Our laboratory has previously
performed limited studies into in vivo seizures and α1A-AR manipulation. However,
these studies have yet to be published and are only tangentially-related to these studies.
The notable exception to this being the observations by Dr. Katie Collette, who
performed the initial characterization of α1A-AR knockout mouse seizure prevalence.
Our observations are a natural extension of that earlier study. Other attempts at in vivo
modeling α1A-AR effects in seizure models are discussed, in detail, within Chapter III.
Briefly, our attempts have shown results consistent with previous attempts to activated
the α1A-AR in acute models of status epilepticus. We found that upon α1A-AR activation,
there is an increase in latency to initial seizure activity. This consistency suggests a
robust effect and lends credence to our findings in hippocampal slices. Further, our
findings suggest, together with our in vitro findings, that α1A-AR activity is necessary for
maintenance of normal seizure threshold and added activation of this receptor subtype
results in moderately increased seizure threshold and resistance.
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Our first set of experiments investigated the effects of cirazoline-mediated α1AAR activation on latency to seizure emergence and progression of severity following
insult with the chemoconvulsant kainic acid. We found that α1A-AR activation increased
the latency to emergence of initial seizure activity. This suggests that α1A-AR activity
increased the seizure threshold. However, we did not find any significant alteration to the
progression of seizure severity during the course of the acute status epilepticus event,
suggesting that α1A-AR activation is insufficient to halt the proliferation of seizure
activity as it progresses. Alternatively, because we administed kainic acid systemically,
these findings may suggest that α1A-AR activation could be sufficient to prevent or
mitigate initial seizure recruitment in especially vulnerable brain regions, but ultimately
unsuccessful at preventing generalized brain seizure activity. This possibility is
especially interesting because certain areas of the brain are known to be vulnerable to
seizure activity, such as the hippocampus, and current evidence does suggest asymmetric
distribution of α1A-AR expression throughout the brain. An interesting experiment would
be to repeat α1A-AR activation and insult brain areas individually. Initially, we had
intended to inject kainic acid locally into the hippocampus and assess these same seizure
criteria. However, it was determined that the follow-up required to assessment of
injection accuracy and precision, as well as the necessity for refinement of dosage would
have significantly limited our experimental throughput. Additionally, even with vehicle
injections, it would be difficult to assess whether the invasive procedure of placing an
injection needle into a deep-brain structure would exacerbate seizures or alter effects
observed.
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Our next experiment was to further characterize spontaneous seizure activity in
α1A-AR knockout mice. Our observations were specifically designed to observe seizure
prevalence in a minimally-stressful environment. This was important because the main
goal of this experiment was to observe if the α1A-AR knockout mice exhibited
unprovoked, recurrent seizures. We found an extremely high prevalence of spontaneous
seizure activity within our sample population. Additionally, we observed several α1A-AR
knockout mice exhibited multiple unprovoked seizures. We provide the time of day and
level of activity during each seizure event. Interestingly, while previous short-term
observations by Dr. Katie Collette (Unpublished) had only found evidence for minimal
convulsive activity (Racine’s Grade 2 or lower), we observed several instances, in
multiple mice, of high grade (Racine’s Grade 4-6) seizure activity. Together, we
concluded that α1A-AR knockout results in a high prevalence of seizures, which are
consistent with the clinical definition of epilepsy in a subset of mice; that is, multiple
unprovoked seizures over a period greater than 24-hours. These findings suggest that
α1A-AR knockout mice may be a model of epilepsy predisposition in mice. Together,
with the conclusions of Dr. Collette, this phenomenon is likely exacerbated with age for
unknown reasons.
In both sets of experiments, we repeated the procedures above with the inclusion
of cortical video-EEG monitoring. Our sample sizes were not large enough to provide
robust conclusions, but were sufficient to make at least one conclusion. Using videoEEG, we were able to conclude that our behavioral categorization of seizure activity was
consistent with distinct abnormal and excessive cortical EEG activity, as measured by
power, line length, and amplitude. This translates to a confirmation that the spontaneous
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seizures, or those induced by kainic acid, were of epileptic nature. This is an important
distinction because there is the possibility of non-epileptic convulsions, which are not
associated with abnormal brain electrical activity. Thus, our implementation was
essential for confirming that our observations and grading of bodily convulsions did
correlate with underlying electrical abnormalities, or in general terms, epileptic seizures.
Further insight was tantalizingly close; we were particularly interested in measuring the
latency to the emergence of abnormal seizure activity, which was not associated with any
behavioral manifestation (sub-clinical seizure activity), because this type of seizure
activity is usually attributed to sub-cortical structures, such as the hippocampus. Finally,
our incorporation of multiple cortical EEG electrodes, in distinct areas across the brain
surface could eventually allow for triangulation of particular areas of interest, should the
necessary surgical throughput and improvement of surgical outcomes become sufficiently
refined. As it stands now, our use of EEG is limited to qualitative assessment, but could
be invaluable should refinement of the surgical procedure become sufficiently easier.
Findings from Immunofluorescence α1A-AR Reporter Staining
The final research project of this dissertation, presented in Chapter IV, aimed to
elucidate the expression patterns of the α1A-AR in the mouse hippocampus. Traditional
methods of visualizing the ARs are unspecific and unreliable due to a high degree of
similarities in nearly all AR targeting moieties (Jensen et al., 2009). This is especially
evident from the publication from the Simpson laboratory showing no reliable antibodies
for the α1A-AR. We utilized β-galactosidase protein production, encoded by the LacZ
operon imparted in the α1A-AR knockout mouse, to garner representative expression of
this receptor. Importantly, the LacZ operon is expressed only under the endogenous α1A103

AR gene promoter and thus is much more likely to exhibit representative patterns of
expression than other models which utilize gene amplification and/or add highly
transcribed promoters. We have had difficulties in the past confirming physiological
function on some populations of neurons that were indicating α1A-AR expression in these
other models.
To our knowledge, the β-galactosidase reporter protein in the α1A-AR knockout
mouse has only previously been utilized for immunohistochemical staining and
assessment of broad patterns of expression in the brain. Thus, it had not been used to
investigate co-localization of the α1A-AR on neuronal sub-populations. Our approach
used immunofluorescence staining techniques to assess β-galactosidase and parvalbumin
expression and co-localization in the mouse hippocampus. We found a small number of
puncta expressed both β-galactosidase and parvalbumin. This suggested that a
subpopulation α1A-AR-expressing cells does colocalize with parvalbumin; and likewise,
that a subpopulation of parvalbumin-expressing cells colocalize with α1A-AR. We were
particularly interested in the α1A-AR status on parvalbumin-expressing cells because
parvalbumin has been shown to almost exclusively be expressed by inhibitory
interneurons (Jiang et al., 2016). Also, our results are consistent with the literature in
suggestions that parvalbumin-expressing inhibitory interneurons are a heterogenous
population, in protein expression, morphology, connectivity, and electrophysiological
properties. This is typical of interneurons, once coined “the butterflies of the soul” by
Santiago Ramon y Cajal (Jiang, 2018).
A secondary conclusion from these experiments were that the α1A-AR reporter
expression was consistent with expression on non-excitatory brain cells. The
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hippocampus is a tightly-laminar brain structure, where excitatory cells are almost
exclusively constrained to two distinct regions, the granule layer of the dentate gyrus and
the pyramidal layer of Ammon’s horn. We observed a moderate level of positive puncta
for β-galactosidase, with a rough estimate of prevalence of about one-fourth that of
parvalbumin-positive cell puncta. Despite this relative commonality, we observed very
few occurrences of β-galactosidase-positive puncta in either the granule layer of the
dentate gyrus, or the pyramidal layer of Ammon’s horn. Importantly, if there was
evidence of excitatory cell expression, one would expect diffuse β-galactosidase reporter
expression on puncta throughout these layers, due to the high degree of homogeneity
typically observed in excitatory cell populations; we did not observe this. This secondary
finding may ultimately be more important to supporting our hypothesis that the α1A-AR
is modulating seizure activity by altering the excitability of inhibitory interneurons.
Consistent with this hypothesis, the pattern of β-galactosidase expression was consistent
with the prevalence and laminar organization of inhibitory populations within the
hippocampus and does not indicate α1A-AR expression on excitatory cell populations.
Significance
The overarching goal of this dissertation research was to further characterize the
contributions of the α1A-AR subtype to the antiepileptic properties of NE. Specifically,
we were interested in further characterizing the specific α1A-AR role in altering seizure
threshold. While our findings show a potential antiepileptic/anticonvulsant effect upon
α1A-AR activation, the effect size was only moderate in our acute seizure models, in vitro
and in vivo. Our identification of epileptiform intensification in vitro and the recurrent
spontaneous and unprovoked seizures observed in vivo, in α1A-AR knockout mice,
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suggests an interesting potential for α1A-AR knockout as a potential avenue to model
epilepsy. However, very little is known about the prevalence α1A-AR mutation in
humans, or the potential ramifications for seizures or epilepsy.
While it is known that the α1A-AR, as well as other ARs, exhibit a fair amount of
constitutive activity, very little exists in the literature about whether this might be
sufficient to explain the detrimental nature of α1A-AR loss on seizure threshold that we
observed. Confirmation studies performed during the construction of the α1A-AR
knockout strain did not reveal any compensatory increases in expression in other α1-AR
subtypes, which lends some credence to the constitutive activity hypothesis.
To our knowledge, there have only been a few documented case studies of α1-AR
manipulations and seizure-related consequences in humans. Briere et al. (1986) showed
reduced α1-AR density in human hippocampi from patients undergoing surgical resection
for drug-resistant epilepsy. Additionally, a more recent case report presented that
tamsulosin (Flomax) treatment, an α1-AR-selective antagonist, exacerbated seizure
prevalence in a patient with temporal lobe epilepsy, and that termination of tamsulosin
treatment returned seizure prevalence to baseline(Ivanez et al., 2006). Both of these
studies suggest an interesting potential correlation between α1-ARs and seizure activity.
Collectively, this research and these case studies may suggest the α1A-AR as a potential
biomarker in epilepsy.
Genetic testing in epilepsy is a growing but still immature field. While there have
long been known specific mutations associated with the development of epilepsy (e.g.
CDKL5, GLUT1, PCDH19, etc.) many epilepsies with clear patterns of inheritance
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remain poorly understood genetically. Generally, there is little information about α1-AR
subtype gene status in epilepsies, possibly due the difficulties involved with protein
quantification unreliability. Additionally, most genetic testing in epilepsy does not yet
involve whole-genome sequencing techniques. Rather, most genetic testing in epilepsy is
targeted at specific genes likely to be altered in seizure disorders, such as those associated
with ion channels and pumps, or metabolic transporters like GLUT1. There are now
several ongoing projects with aims to sequence the genomes of large populations of
epilepsy patients, but most current available information focuses on broad chromosomal
abnormalities. Even so, it is highly likely that genetic patterning in epilepsy will be
highly heterogeneous and inconsistent based on the spectral and syndromic nature of the
disease. We hope that our findings may encourage clinicians to implement analysis of
α1-AR subtype status in epilepsy.
Conclusions
This dissertation research has made significant contributions to our understanding
of the functions and consequences of the α1A-AR, especially pertaining to the role of this
receptor to seizures and epilepsy. Our research took a translational approach, focusing on
the functional consequences of α1A-AR expression and activity, rather than a purely
mechanistic approach. However, our experiments were meticulously planned in method
and technique so that they were similar and complementary to our previous efforts to
unravel the mechanism(s) of α1A-AR action. We were especially careful to perform
experiments which were translatable in vitro and in vivo. Thus, using deductive
reasoning, we can build upon our previous conclusions to expand our current working
hypothesis: α1A-AR activation elicits antiepileptic effects, particularly a shift in seizure
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threshold, likely mediated by increased resting membrane potential and increased rate of
action potentials in hippocampal inhibitory interneurons, mediated via increased
conductance of potassium channels and funny current. Put more simply, our observations
suggest that α1A-AR activity is critical for maintenance and modulation of excitatoryinhibitory balance in the brain, with measurable consequences for epileptic seizures.
More broadly, this research has significantly contributed to our understanding of
the central noradrenergic system. We have developed novel methodologies for
selectively measuring the contributions AR subtypes to NE action. The applicability of
the findings in this dissertation are not limited only to seizures and should be easily
transferable to other experimental paradigms. If not directly useful to a researcher, the
techniques and methodologies used here clearly show the value of combining multiple
approaches to understand a research question; for our experimental paradigm, the
implementation of transgenics has become a necessity to further elucidate the
mechanisms and functionality of the α1A-AR. Eventually, it may become possible to
selectively target and characterize the α1A-AR using conventional methods, but current
pharmacological ligand and antibody selectivity do not allow for the necessary accuracy
and reproducibility to garner useful information. Interestingly, but not surprisingly, the
efforts of our laboratory and those of our collaborators closely mimic the path of historic
progression that has led the researchers of NE and the ARs to be so influential for the
development of receptor theory, pharmacology, and many other fields. The
noradrenergic system is extremely complex, but necessity is the mother of invention, or
so they say.
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Clinically, this research has significance in furthering our understanding of
seizures, seizure threshold, and the potential of interneuron-based therapies in epilepsy.
Our research showed the specific contributions of α1A-AR activation to noradrenergic
antiepileptic effects in multiple models of epilepsy. We showed evidence suggesting that
α1A-AR activation can partly mitigate actively-elicited epileptiform and seizure activity.
While more difficult to measure and control for extraneous variables, the α1A-AR may
prove more efficacious in chronic models of epilepsy, where a shift in inhibitory
threshold may be more consequential in the prevention of ictogenesis. These results
seems especially worthwhile when considering our previous findings about the
neurocognitive benefits of α1A-AR activation; this presents a possibility that an α1A-ARbased therapy may be dually beneficial as a seizure treatment with minimal, or possibly
beneficial, neurocognitive consequences. Another fascinating contribution of this
research were our findings which assessed the detrimental effect of α1A-AR knockout on
exacerbation of epileptiform characteristics and to spontaneous, recurrent epileptic
seizures observed in vivo. While genetic and transcriptome analysis is still an emerging
field in epilepsy, our findings strongly suggest that deleterious α1A-AR mutations may
increase vulnerability to ictogenesis.
Collectively, these results suggest potential clinical potential for the α1A-AR both
as an epilepsy therapy and potential biomarker. Finally, these results may also be
applicable to neurocognitive disorders other than epilepsy. Our findings, and those of
previous researchers, suggest that both α1A-AR activation and loss-of-function has
physiological consequences for neural circuit function. Thus, these findings may
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translatable to many neurocognitive disorders which involve neurophysiological
imparement.
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